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Estrogen receptor α (ERα) is a ligand-inducible hormone nuclear receptor that has 
important physiology and pathology roles in various human systems.  Our work focused 
on understanding the combinatorial complexity of ER regulatory control on a genomic 
scale. In our earlier studies (Joseph et al, 2010; Lin et al, 2007) we found that FOXA1 
and GATA3 motifs were commonly enriched around ERα binding sites. We then pursued 
the question of binding site selection and found that though sequence was the most 
important determinant, the presence of FOXA1 binding and DNA Pol II binding were 
important secondary characteristics that are associated with ER binding site selection. 
Numerous microarray studies have documented the co-expression of ERα, FOXA1 and 
GATA3 in primary breast tumors (Badve et al, 2007; Wilson and Giguere, 2008). These 
evidences suggest that potentially these three transcription factors (TFs) function 
conjointly to contribute to the breast cancer phenotype. However, the nature of their 
coordinated interaction at the genome level or the biological consequences of their co-
expression remains poorly understood.   
To extend these observations, we mapped the genome-wide binding profiles of ERα, 
FOXA1, and GATA3. We observed that these three TFs co-localized in a coordinated 
fashion upon estrogen stimulation.  Moreover, we found that the ERα+FOXA1+GATA3 
conjoint sites were associated with highest p300 coactivator recruitment, RNA Pol II 
occupancy, and chromatin opening. Such results indicate that these three TFs form a 
functional enhanceosome and cooperatively modulate the transcriptional networks 
previously ascribed to ER alone. In addition, such enhanceosome binding sites appear 
to regulate the genes driving core ER function.  
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Though ERα is known to mediate the proliferative effects of estrogen (E2) in breast 
cancer cells, the exogenous introduction of ERα into an ERα-negative line displayed 
inhibited growth (Garcia et al, 1992). We posited that the composition of enhanceosome 
is required to establish transcriptional regulatory cassettes favoring growth enhancement.   
To test this, we stably transfected the MDA-MB-231 cells with individual ERα, FOXA1, 
GATA3 or in combinations. We demonstrated that the co-expression of 
ERα+FOXA1+GATA3 resulted in marked induction of estrogen-stimulated growth. This 
cellular reprogramming was recapitulated in another ERα-negative breast cancer cell line, 
BT-549 and observed similar E2-responsive growth induction in the 
ERα+FOXA1+GATA3-expressing cells. This suggests that only with the full activation 
of conjoint binding sites by the three TFs will the proliferative phenotype associated with 
ligand induced ER be manifest. 
To assess the nature of this transcriptional reprogramming, we compared the expression 
profiles of the reprogrammed MDA-MB-231 and BT-549 cells with the ERα-positive 
breast cancer cell line, MCF-7. Strikingly, we found that the expression profiles of 
ERα+FOXA1+GATA3 expressing MDA-MB-231 and BT-549 cells display positive 
correlation with the E2 induced expression profile of MCF-7. In contrast, negative 
correlation was found in the MDA-MB-231 and BT-549 transfected with ERα only. 
Furthermore, we observed that the enhanceosome component is competent to partially 
reprogramme the basal cells to resemble the luminal cells.  
Taken together, we have uncovered the genomics impact as well as the functional 
importance of an enhanceosome comprising ERα, FOXA1 and GATA3 in the estrogen 
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responsiveness of ERα positive breast cancer cells. This enhanceosome exerts significant 
combinatorial control of the transcriptional network regulating growth and proliferation 
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CHAPTER 1: INTRODUCTION 
 
1.1 The physiological and pathological roles of estrogen  
Estrogen has widespread biological functions in numerous human tissues and diseases. It 
stimulates the growth of reproductive systems, maintains the bone density by mediating 
the function of osteoclasts and exerts cardiovascular protection effects through its 
vasodilation properties in the vascular smooth muscle (Grodstein et al, 2000) (Figure 1). 
The estrogen  has also encompassed the neuroprotective roles in the brain tissues by 
inducing the synaptic and dendritic activation (Naftolin et al, 1999). Moreover, estrogen 
can enhance the lipoprotein receptors leading to the reduction of low-density lipoprotein 
(LDL) cholesterol in the serum (Paganini-Hill et al, 1996).   
Though estrogen exerts several beneficial roles in various human tissues, increased 
exposure to estrogen possessed harmful effects in raising the breast and endometrial 
cancer risks by stimulating the growth of tumor cells (Bernstein, 2002).  
The complex mechanisms by which these effects are mediated remain incompletely 
understood. The major question is how a single nuclear hormone receptor can provide 
such disparate phenotypic and molecular outputs dependent on the tissue or origin. Hence, 







Figure 1. The physiological and pathological roles of estrogen in various human organ 









1.2 The structure of estrogen receptor 
The identification of estrogen receptor (ER) by Jensen and Jacobsen in 1960 has shifted 
the paradigm of steroid hormone action from the enzymatic mode to the current model of 
estrogen regulation by a receptor protein (Jensen and Jacobson, 1960). The pleiotropic 
effect of estrogen is largely mediated by its receptor, ER, which is a member of the 
nuclear receptor superfamily.   
The ERα gene is located at 6q25.1 that extends more than 140kb. It contains eight exons 
and encodes a protein of 595 amino acids with a predicted molecular weight of 66,182 
Dalton (Figure 2). The human ER has the typical structure resembles to the other class I 
members of ligand-inducible steroid receptor superfamily. It consists of six functional 
domains designated as A – F: the amino-terminal A/B domain with the hormone-
independent activation function (AF-1); the middle C domain contains the DNA binding 
domain (DBD) consisting of two zinc finger motifs that are responsible for ER binding to 
estrogen responsive elements (EREs) and dimerization; the D domain – the hinge region 
is implicated in co-regulatory protein binding; the carboxy-terminal domains E and F 
contain the ligand binding domain (LBD) that are implicated in modulating the agonist 
activity. ER is a predominantly nuclear protein regardless of whether or not it is 





Figure 2. The structure of ESR1 gene at 6q25.1 spans more than 140kb and contains 8 
exons. The ERα protein is composed of 595 amino acids and organized into A to F 













1.3 The estrogen receptor subtypes 
ER is classified into ERα and ERβ subtypes (Witkowska et al, 1997) that composed of 
highly homologous DNA-binding domain but varies in the ligand-binding domain of 
which only 58 percent of the amino acid sequence is shared (Figure 3).  
The distribution of ERα and ERβ also varies in different tissues. ERβ presents mostly in 
brain, kidney, intestinal mucosa and prostate gland. In contrast, the classical estrogen 
target tissues such as breast, endometrium and ovarian stroma contain mostly ERα 
(Figure 4).  
The most striking phenotypes in the female ERα knockout (ERαKO) mice include 
estrogen insensitivity in the reproductive tract, lack of pubertal mammary gland 
development and excess adipose tissue, whereas in the male, testicular degeneration and 
epididymal dysfunction are major phenotypes (Couse JF. and S., 1999). These 
phenotypes combined with severe deficits in sexual behavior result in complete infertility 
in both sexes of the ERαKO mice. In contrast, ERβKO males are fertile and show no 
obvious phenotypes while the female ERβKO mice exhibit inefficient ovarian function 
and subfertility. Interestingly, combine ERα and ERβ knockout mice (ERαβKO) exhibits 
phenotypes that mostly resemble those of the ERαKO, suggesting that ERα plays a more 
predominant role in development. 
The diverse composition and responsiveness of ERα and ERβ to different ligands has 
initiated the search for tissue-selective estrogen receptor modulators (SERMs) with the 




estrogen in the target tissues and avoid the unwanted harmful side effects, which will be 
extremely useful in the treatment of menopausal symptoms, osteoporosis, cardiovascular 
disease and breast cancer in women. 
 
1.4 The mediation of estrogen by estrogen receptors  
There are two models of ligand-dependent activation of ER exist to date: the ‘classical’ 
activation induced by agonists which results in direct interaction of the ER with DNA and 
subsequent transcription activation; and the ‘non-classical’ activation induced by the 
agonists which cause the interaction of ER with other proteins which in turn, bind to 
DNA and modulate transcription.  
The classical estrogen signaling pathway reveals that upon the estrogenic stimulation, 
ligand binding leads to conformational changes of the receptor which causes the 
dimerization of the receptors. The activated ER will diffuse into the nucleus, bind to its 
DNA recognition sequences known as estrogen response elements (EREs) and initiate the 
transcription of its target genes (Figure 5). The 13-bp inverted repeat sequences 
5’GGTCAnnnTGACC’3 (n denotes a random nucleotide) are defined as the binding 
motif of ER that is present in the regulatory regions of the estrogen target genes (Walker 
et al, 1984). Upon binding to an ERE, the ligand-activated ER complex will interact with 
















Figure 4. The distribution of ERα and ERβ mRNA in various tissues of the mouse. The 
ERα mRNA is broadly distributed in many tissues whereas the ERβ transcripts are 
primarily expressed in the ovary, hypothalamus, lung and male reproductive tract (Couse 






Figure 5. The illustration of classical estrogen signaling pathway mediated by ER. The 
ligand-activated ER will diffuse into the nucleus, bind to its DNA recognition sequences 
known as estrogen response elements (EREs) and initiate the transcription of its target 
genes (Gruber et al, 2002). 
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According to the ‘non-classical’ model of ER activation, ligand binding leads to the 
interaction of ER with other transcription factors (TFs) such as AP-1, SP1 or NF-κB 
(Figure 6). These complexes bind to DNA through direct interaction of the ER-associated 
TFs, thus influencing the transcription of genes which do not contain EREs but rather 
have recognition sites specific for AP-1, Sp1 or NF-κB (Webb P. et al, 1999). This ‘non-
classical’ model also known as ‘transcription factor crosstalk’ occurs without the direct 
ER binding to the DNA. 
Another “non-genomic” pathway also exist, whereby the estrogen activates kinase 
cascades such as MAPK and/or PI3K that activate other transcription factors by 
phosphorylation and induce gene expression (Figure 6). The ability of estrogen to 
activate non-genomic kinases such as ERK and AKT may depend on the expression level 
of peptide growth factor receptors and the signaling kinases in the cells. “Non-genomic” 
estrogen signaling is transduced by a membrane-localized pool of ER, which can rapidly 
activate both ERK and AKT in response to estrogen. However, this estrogen-induced 
cytoplasmic signaling is restricted in cells that express high levels of growth factor 






Figure 6. Illustrations of models representing the various modes through which ER can 
modulate transcription machinery. In the “classical” pathway, estrogen binds to ER, 
which in turn translocates to the nucleus, binds DNA at the ERE and activates the 
expression of ERE-dependent genes. In the “non-genomic” pathway, estrogen activates 
kinase cascades such as MAPK and/or PI3K that activate TFs by phosphorylation and 
induce gene expression. In the “transcription factor crosstalk” pathway, ER is activated 
by estrogen and enhances gene transcription through indirect DNA-binding with other 











1.5 The function of estrogen receptor as the DNA-binding transcription factor in 
gene regulation 
The activity of transcription factors (TFs) was one of the first proposed mechanisms of 
gene regulation many decades ago. Since the exciting discoveries of various chromatin 
marks and associated remodeling factors for the last 15 years, epigenetic modifications 
have largely dominated the general view of how eukaryotic genomes are transcriptionally 
regulated. However, the recent ground-breaking reprogramming studies to generate the 
induced pluripotent stem (iPS) cells from the fibroblast with four TFs have reminded the 
field about the power and supremacy of TFs. Most importantly, this have reinforced the 
notion that both the TFs regulation and epigenetic modifications are important 
contributors to eukaryotic gene regulation (Takahashi K and S., 2006; Takahashi K et al, 
2007). 
The complex human body consists of many systems that are specified by their unique 
transcriptional programs. A finely tuned modulation of transcription activity requires the 
coordination of numerous regulatory events and mechanisms involving the DNA-binding 
TFs, coactivators, corepressors and basal RNA polymerase machinery (Figure 7). 
Nuclear hormone receptors regulate various biologically important processes in the 
development and homeostasis through their bimodal function as activators and repressors 
of gene transcription. This precise cell- and time-specific regulation is crucial for the 





Figure 7. The regulation of gene transcription orchestrated by coactivators, corepressors 
and basal RNA polymerase machinery. Coactivators complexes include factors that 
contain ATP-dependent chromatin remodeling activity, histone acetyltransferase, histone 
arginine methyltransferase that are involved in RNA processing. Conversely, 








The key question in transcription regulation field is deciphering how an organism can 
achieve such diversity, while maintaining cell specificity and responding dynamically to 
its environment. One possible explanation is to employ a restricted repertoire of 
activators as to minimize the complexity required to link the related signaling pathways 
and orchestrate diverse regulatory cues. 
The current model of ER function as a TF implies that ER modulates the transcription 
machinery via the recruitment of a variety of coactivators or corepressors and chromatin 
remodeling enzymes to the promoters and enhancers regions (Shang et al, 2000). 
Transcriptional activation involves alterations in chromatin structures mediated by the 
ATP-dependent chromatin-remodeling enzymes in conjunction with factors that contain 
histone acetyltransferase (HAT) property that leads to the decondensation of chromatin 
structure, which is a prerequisite for gene transcription. A large number of co-factors are 
implicated in these chromatin remodeling processes such as p300 and CBP. The specific 
and ordered recruitment of multiple protein complexes to the chromatin will then 
provides the chromatin with the plasticity required for the transcription initiation (Cosma, 
2002). However,  our understanding in this multifaceted gene regulation is still 
fragmentary as the range of possible combinations of different players and their 
remoteness from the transcription start sites (TSS) of regulated genes suggest multiple 
regulatory mechanisms (Farnham, 2009).    
ERα is also known to commonly induce long distance chromatin interactions between 
ERα binding sites and TSS through chromatin looping (Fullwood et al, 2009), suggesting 
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that higher dimensional structural order beyond the simple receptor-recognition motif 
interaction is essential in explaining ERα directed transcriptional regulation.   
The enhanceosome assembly is dependent on the arrangement of precise component of 
bound activators, which together generate a network of protein-protein and protein-DNA 
interactions unique to a given enhancer (Carey M., 1998). As illustrated in Figure 8, the 
enhanceosome displays an assembly of activator-activator interactions on the naked DNA 
or chromatin templates. Reciprocity is essential in this process whereby the 
enhanceosome recruits the RNA Pol II machinery and the machinery reciprocally 
facilitates assembly of the enhanceosome. This provides an additional specificity and 
energy required to drive the concerted formation of the final “transcriptome”.  
The finding that transcription factors (TFs) cluster at juxtaposed binding sites in the 
genome to form enhanceosomes further suggests that the totality of gene regulation by 
any transcription factor will be dependent on a complex interaction between specific ERα 
binding, local configuration of co-occupying TFs, protein co-factors, chromatin 





Figure 8. The assembly of enhanceosome components to Pol II preinitiation complex in a 
multistage process. Initially, the activators engaged to the chromatin in a cooperative 
manner and formed a stable enhanceosome. This is followed by the recruitment of Pol II 
and its ancillary factors to DNA and resulted in synergistic transcription that is driven by 










1.6 The co-expression of estrogen receptor α, FOXA1 and GATA3 in breast cancer  
Breast cancer is a molecularly heterogeneous disease whereby the tumors could be 
classified into different subtypes of distinct molecular portraits with prognostic 
significance. This heterogeneity has spawned an era of molecular assays striving to 
classify the tumor subtypes to predict the disease outcome and provide useful guidelines 
to the future of targeted personalized treatment strategies.  
Since the innovation of microarray technology a decade ago, systematic characterization 
of gene expression profiles in human breast tumors have provided better understanding in 
the molecular taxonomy of breast cancers (Figure 9). In particular, these microarray 
studies have identified distinctive molecular subtypes – luminal A/ B, ERBB2-associated, 
basal-like, claudin-low subtype and normal-like breast tumors based on gene expression 
profiling patterns as well as copy number alterations (Perou et al, 2000; Prat et al, 2010; 
van't Veer et al, 2002). 
Patients with ERα-positive breast cancers usually have better prognosis which is partly 
due to their response to endocrine therapy. Both luminal subtypes A and B are ERα 
positive with a more favorable outcome in luminal A tumor as compared to luminal B 
tumors with higher proliferation rate and frequent DNA amplification. The ERBB2 
subtype is associated with expression of genes co-amplified with ERBB2 (encoding 
HER2). The aggressive basal-like tumors are ERα-, progesterone receptor- (PR) and 
ERBB2-negative, hence also known as triple-negative tumors are associated with poor 
outcome. The claudin-low tumors lack common epithelial cell features and is enriched 
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for tumor initiating cell (TIC) features. The normal-like subtype shares expression 
patterns with normal breast tissue. Due to the unique biology and prognostic features in 
various breast tumor subtypes, it has become appreciated that breast cancer is not one 
disease, but in fact represents multiple disease types whereby each of which requires a 
unique treatment modulation. 
Since ERα has been implicated in the etiology of breast cancer, it is a major prognostic 
marker and therapeutic target in breast cancer. Interestingly, the co-expression of ERα, 
FOXA1 and GATA3 has been reported in different cohorts of luminal breast cancer 
tumors (Lacroix M and G., 2004; Oh DS et al, 2006; Sorlie T et al, 2003). Therefore, it is 
essential to gain a better understanding in the transcription networks mediated by ERα 








Figure 9. The hierarchical clustering of 115 tumor tissues and 7 non-malignant tissues 
based on the distinctive molecular signatures. (A) The dendrogram showing the 
clustering of the breast tumors into five subgroups. (B) Gene cluster associated with 
ERBB2 amplification. (C) Gene cluster associated with luminal subtype B. (D) Gene 
cluster associated with the basal subtype. (E) Gene cluster relevant for the normal breast-
like group. (F) Gene cluster associated with luminal subtype A tumors with co-expression 
of ERα (ESR1), FOXA1 (HNF3A) and GATA3. Scale bar represents fold change for any 
















Patients with ERα positive tumors have a longer disease-free interval and overall survival 
than patients with tumors lacking ERα expression. According to international treatment 
guidelines for early breast cancer, patients with ERα and/ or PR expression should 
receive an adjuvant anti-hormonal endocrine therapy. However, the association between 
ERα expression and hormonal responsiveness is far from perfect, since approximately 30% 
of ER-positive tumors do not respond to hormonal treatment and 5 to 15% of ER-
negative tumors curiously respond to endocrine therapy (Jordan VC et al, 1988). Hence, 
the expression of FOXA1 and GATA3 as the useful prediction marker for patient 
response to hormonal treatment has been proposed by several studies (Badve et al, 2007; 
Mehra et al, 2005; Oh DS et al, 2006).  
Among the ER-positive tumors, expression of FOXA1 mRNA was noted in tumors that 
showed favorable outcome (Oh DS et al, 2006). When the FOXA1 protein expression in 
breast cancers was analyzed by immunohistochemistry (IHC), FOXA1
high
 (score greater 
than 3 by IHC) was associated with ERα positivity, GATA3 positivity and luminal A 
subtype (Badve et al, 2007). Most importantly, improved event-free survival was seen in 
these patients compared with patients in the FOXA1
low
 group even at 20 years.  
Another clinical study involving over 3500 primary invasive ductal carcinomas 
demonstrated positive FOXA1 staining in ~86% of all specimens, and expression was 
positively correlated with favorable prognosis. In consistent with the finding by Badve et 
al, low FOXA1 was correlated with established markers of poor prognosis including high 
grade, increased tumor size, basal tumors and nodal metastasis (Mehta RJ et al, 2011).   
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The meta-analysis of breast cancer microarray datasets involving 305 breast tumor 
samples from four breast cancer cohorts (Huang E et al, 2003; Lonning PE et al, 2001; 
Sotiriou C et al, 2003; van de Vijver MJ et al, 2002) revealed that low GATA3 
expression was strongly associated with higher histological grade, positive lymph nodes, 
larger tumor size, ER and PR-negative status, HER2 overexpression and greater risk for 
recurrence or metastasis (Mehra et al, 2005). This observation recapitulated the similar 
finding in the association of poor prognosis with low FOXA1 level (Figure 10). 
Cumulatively, these findings suggested that better delineation on the roles of ERα, 
GATA3 and FOXA1 in breast cancer will be useful for accurate diagnosis, predicting 
endocrine responsiveness, form the basis for novel therapeutic strategies and assess the 
patient’s outcome.  
 
1.7 The differential estrogen receptor α binding is associated with clinical outcome 
in breast cancer 
Though ERα is the major determining factor in dictating the cellular growth and 
endocrine response of breast cancer cells, the comprehensive understanding of ERα 
function remains fragmentary. The recently published work by Ross-Innes et al (Ross-
Innes C.S. et al, 2012) has mapped the ER binding events in primary breast cancers from 
patients with different clinical outcomes. Using the differential binding analysis (DBA) 
and principal component analysis (PCA) approaches, they reported differential ERα 
binding events in the primary breast tumors with good prognosis, poor prognosis and 
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distant metastases (Figure 11A). The genes that are associated with these distinguishable 
ER binding profiles are capable of discriminating the clinical outcome (Figure 11B), 
suggesting that the ER binding to cis-regulatory elements is functionally and biologically 
relevant. This sheds lights on the importance and relevance of TF binding in modulating 












Figure 10. The Kaplan-Meier plot showing the improved cancer-specific survival in 
patients with (A) FOXA1
high
 score (Badve et al, 2007) and (B) high GATA3 expression 












Figure 11. (A) The differential ER binding events that are statistically enriched in either 
the patients with good outcome (599 ER-binding events) or patients with poor outcome 
and metastases (1,192 ER-binding events). (B) The genes within 20kb of the differential 
ER-binding events were useful to predict distant metastases-free survival outcome (Ross-









1.8 FOXA1 as the key pioneering factor for estrogen receptor activation 
The forkhead box A1 (FOXA1) transcription factor was initially discovered to regulate 
liver and other gut organ-specific genes which are necessary for the development of the 
endoderm and liver, hence it was named as hepatocyte nuclear factor 3α (HNF3A). Based 
on the homology of this protein to Drosophila forkhead proteins, HNF3A was later 
renamed to FOXA1 in 2000.  
FOXA1 is expressed in the developing mammary gland in conjunction with ERα. Report 
by Bernado et al has demonstrated that FOXA1 is present within the structures that are 
necessary for mammary morphogenesis and it is expressed in the same developmental 
stages as ERα (Figure 12). Furthermore, they showed that FOXA1 is required for ERα 
expression in the mammary epithelium where there is undetectable ERα within the 
epithelium of FOXA1
-/-
 glands (Figure 13) (Bernado GM et al, 2010).  
FOXA1 has the winged helix structure which has a helix-turn-helix core of three α-
helices flanked by two loops. It binds to the DNA as monomers by recognizing the seven-
nucleotide RYMAAYA (R = A or G; Y = C or T; M = A or C) consensus (Pierrou S et al, 
1994). A winged helix fold remarkably similar to that of forkhead proteins is found in the 
linker histone H1 and H5, this permits the C-terminus of FOXA1 to interact with histone 




Figure 12. The FOXA1 and ERα expressions at different stages of the developing 
mammary gland. (A) Representative images of virgin terminal end buds (TEBs) (5 
weeks), virgin ductal epithelium (8 weeks), virgin alveoli (20 weeks), pregnant alveoli 
(day 18), lactating alveoli (day 2) and an involuting gland (day 5). (B) The 
immunofluorescent image of ERα and FOXA1 in the virgin ductal epithelium (Bernado 




Figure 13. FOXA1 is required for expression of ERα in the normal mammary gland. 
Images of ERα and PR expressions in the mammary gland of Foxa1-/- mice harvested 4-5 
weeks post-transplantation. There is depleted ERα and PR expression in Foxa1-/- mice  












and co-workers suggested that this structural similarity is functionally significant. The 
binding by FOXA1 to nucleosomes was independent of the histone acetylation, it 
converted the chromatin to a confirmation that permits binding of additional TFs (Cirillo 
et al, 2002). Consequently, the FOXA1 protein has been proposed to operate as ‘pioneer’ 
factor that can displace linker histones from the compacted chromatin and facilitate the 
binding of other TFs. 
Factors that facilitate DNA binding of liganded steroid receptor to chromatinized DNA in 
vivo were poorly understood. The study by Carroll et al on the mapping of ERα binding 
sites in chromosomes has revealed a specific role for FOXA1 as pioneering factor which 
prepares genomic sites for the recruitment of ERα to ~50% of target genes (Carroll et al, 
2005).   
Recent work by Hurtado et al further suggested that FOXA1 is the primary determinant 
of ER binding and transcriptional activity in breast cancer cells (Figure 14), under both 




Figure 14. FOXA1 is required for estrogen and tamoxifen-responsive growth. (A) The 
MCF-7 cells demonstrated repressed growth in the absence of FOXA1. (B) The 
hormone-depleted Tamoxifen-resistant (Tam-R) MCF-7 cells displayed inhibited cell 









Report by Lupien et al demonstrated that cell type-specific recruitment of FOXA1 to the 
chromatin is linked to the breast and prostate cancer transcriptional programs through 
specific collaborations with ERα in breast cells and androgen receptor (AR) in prostate 
cells (Lupien et al, 2008). Their work has further illustrated how FOXA1 recruitment 
occurs primarily on H3K4me1/me2 regions and regulates differential transcriptional 
programs through its collaborations with cell type-specific TFs (ERα and AR) as well as 
ubiquitously expressed TFs (AP-1 and Sp1) (Figure 15). 
Though FOXA1 has been implicated as the pioneer factor with the capability to open the 
closed chromatin and facilitate the binding of other TFs, a substantial fraction of FOXA1 
bound sites still harbor relatively closed chromatin structure with low formaldehyde 
assisted isolation of regulatory elements (FAIRE) signals (Eeckhoute et al, 2009). This 
indicates that FOXA1 recruitment is required, but it is not sufficient to trigger full 
opening of the chromatin and induce full functional activity for positive gene regulation 
(Figure 16). This observation has highlighted that FOXA1 may require a repertoire of 
collaborating TFs to promote chromatin opening and may impart the cell-type specificity 
of FOXA1 function. Herein, we hypothesized that ERα and GATA3 are such 





Figure 15.  An illustration of ER-mediated transcription in breast cancer cells. FOXA1 
interacts with the cis-regulatory regions in heterochromatin and facilitate the interaction 
of ER with chromatin, follows by p160 cofactors recruitment and histone modification 





Figure 16. By using FAIRE as the tool to isolate genome-wide nucleosome-depleted 
DNA, a feature of opened human chromatin, Eeckhoute et al has demonstrated that a 
fraction of FOXA1 bound sites only harbors low FAIRE signal with closed chromatin 
feature. (A) The average FAIRE array signal was classified as low, medium and high 
FAIRE in MCF-7 human breast carcinoma cells and the unique LNCaP human prostate 
carcinoma cells.  (B) Signals from FOXA1 ChIP-on-chip in MCF-7 cells were divided 










1.9 GATA3 as the driver of luminal differentiation in mammary gland and co-
regulator of ER transcription in breast cancer cells 
GATA3 was originally identified as an erythroid cell-specific DNA binding protein that 
bound to WGATAR consensus sequences (W indicates A/T and R indicates A/G) found 
in the regulatory regions of many erythroid-specific genes (Wall L. et al, 1988). It is 
important in the development of T-cells, nervous system, kidneys and hair follicle. Its 
targeted disruption is embryonically lethal with abnormalities including severe 
aberrations in the nervous system and fetal liver hematopoiesis (Pandolfi PP et al, 1995).  
GATA3 has been found to be an essential TF for the active maintenance of luminal 
epithelium in the mouse mammary gland. Targeted deletion of GATA3 resulted in 
severely diminished mammary epithelial structures, delayed ductal branching (Figure 17), 
impaired lactogenesis and reduced lobuloalveolar development (Asselin-Labat et al, 2007; 
Kouros-Mehr H et al, 2006). The GATA3 deficiency led to an expansion of an epithelial 
population lacking markers of luminal cells and causing a concomitant block in 
differentiation.  Interestingly, reminiscent of the finding on the inter-dependency of ERα 
and FOXA1 expression in the mammary epithelium (Bernado GM et al, 2010), the ERα 
expression was also affected in the GATA3-depleted mice, suggesting that these three 






Figure 17. Disrupted development in the MMTV-cre; Gata-3
f/f
 deleted mammary gland 
comparing to the wild-type control mice. (A) Restricted expansion of the ductal tree 
within the fat pad of the Gata-3 deleted mice. (B) Immunostaining of ERα in the 
mammary gland sections from 8-week-old virgin mice revealed that depleted ERα 







GATA-3 has also been described to possess chromatin remodeling abilities (Shoemaker J 
et al, 2006) whereby ectopic expression of GATA-3 in naïve primary CD4+ cells directly 
increases chromatin openness at the IL-10 enhancer as well as inducing long-range 
remodeling of known positive regulatory regions (Figure 18).  
GATA-3 is hypothesized to be integral to the ERα pathway supported by the following 
observation: (1) there is large overlap of the co-expressed genes revealed by meta-
analysis between GATA3 and ERα, (2) the highest associated co-expressing gene for 
GATA3 was ERα and vice-versa, (3) GATA3 and ERα co-expressed with many well-
known ERα pathway partners such as pS2 (Wilson and Giguere, 2008). Furthermore, 
ERα has been shown to directly stimulate the transcription of GATA3 gene, indicating 
that these two TFs form a positive cross-regulatory loop that mediate the pro-proliferative 
signal of estradiol in breast cancer cells (Eeckhoute et al, 2007). 
Although the coordinate expression and the importance of GATA3 in mammary cell 
development and differentiation have been well documented, the role of GATA3 in 
breast cancer is less clear and little experimental data is presently available. Hence, the 
need for a more complete understanding of the role of GATA3 in the regulation of ERα 







Figure 18. GATA-3 induced changes on the chromatin structure at the Il-10 locus. (A) 
Schematic of the fragments of the Il-10 genomic locus analyzed in this study. (B) IL-4
-/- 
naive T cells were transduced with a mock retrovirus (Mock-RV) or a GATA-3-
expressing retrovirus (GATA3-RV). In the presence of ectopic GATA-3, the chromatin 
accessibility at the Il-10 locus was increased. This effect was most pronounced at sites 
located in the proximal 5’-region of the Il-10 gene (HSS -0.860 and HSS -0.610). 
Chromatin remodeling was also observed at HSS +6.40, suggesting that GATA-3 may 













1.10 The estrogen response cassette in driving the growth and proliferation of breast 
cancer cells 
Estrogen signaling is fundamental to normal mammary gland development and plays a 
central role in promoting the proliferation of neoplastic breast epithelium. There is long-
standing epidemiological evidence that estrogen affects the risk of breast cancer. 
However, the knowledge and understanding on how this hormone controls human breast 
development, proliferation and differentiation, and how its action on normal human 
breast epithelial cells relates to breast cancer risk is still fragmentary.  
A hallmark of cancer cells is faulty decision-making: they proliferate when they should 
be quiescent; they survive when they should be dying, and they invade and move around 
when they should remain idle. The exact role of estrogen-mediated gene regulation in 
breast cancer and the manner in which these changes in gene expression affect breast 
cancer proliferation and progression are far from clear. 
ERα is expressed in a subset (only 5-10%) of normal breast epithelial cells and these 
ERα-expressing epithelial cells do not normally proliferate in response to estrogen 
(Clarke RB. et al, 1997). In contrast to the normal breast, most pre-malignant breast 
lesions (~70%) express high levels of ERα and proliferate upon estrogenic stimulation. 
The answer to why do ERα-containing breast cancer cells divide in response to estrogen 
is still lacking. It is possible that ERα suppresses expression of certain growth factor 
receptors in normal mammary epithelium and that upon estrogen withdrawal, as occurs 
during menopause, there is expression of growth factor receptors on ER-positive cells. 
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Once this has occurred, ER can no longer inhibit the growth factor-stimulated tyrosine 
kinases and the normal regulation of cell growth is lost (Nilsson S et al, 2001). 
Current endocrine therapies for ER-positive breast cancers aim at abrogating the ER 
function at multiple levels. These include ablating the estrogen level, obstructing estrogen 
action at the ER, and decreasing ER levels. However, the ultimate effectiveness of these 
therapies is limited by either intrinsic or acquired resistance. Elucidating the factors and 
pathways responsible for sensitivity and resistance remains a challenge in improving the 
treatment of breast cancer.  
Though estrogen-activated ERα is believed as the prime inducer for the proliferation of 
breast cancer cell, the finding by Garcia et al has yielded unexpected observation where 
exogenous introduction of ERα into an ERα-negative MDA-MB-231 breast cancer cells 
shown inhibited growth upon estrogenic stimulation (Figure 19), indicating that factors 
other than the estrogen receptor are involved in the estrogen-dependent proliferation of 
breast cancer cells (Garcia et al, 1992). 
The spatio-temporal expression of ERα and its cofactors is likely to dictate the 
physiological effects of estrogen. The genetic mechanisms that program cellular growth 
and proliferation in mammary cells remain to be defined, but it seems likely that these 
decisions are orchestrated by specific combinations of TFs. Although it is poorly 
described whether co-regulators levels are related to breast carcinogenesis, it seems likely 
that changes in the levels or activity of co-regulators would have profound effects on 






Figure 19. Inhibition of proliferation of MDA-ER cells by estrogen. The MDA-ER cell 
lines (HC1 and HE5), the control transfected cell line (PB4), and ER-positive breast 
cancer cell line MCF7 were treated with 20 nM estradiol (•) or ethanol vehicle alone (o) 
up to 12 days with a medium change every 2 days. The DNA content was determined by 
















A positive association between lack of GATA3 and FOXA1 expression and lack of 
response to hormonal therapy suggests that these TFs may play a role in mechanisms 
controlling response to estrogen (Hurtado A et al, 2011; Parikh P et al, 2005). A role for 
FOXA1 and GATA3 in mediating ERα activity is also suggested by the presence of their 
specific binding sequences in the promoter of genes involved in both the synthesis 
(HSD17B1) and the degradation (CYP3A4) of E2 (Lacroix M et al, 2004).  
Harnessing the exact role of many molecular players of ER signaling in regulating the life 
and death of a breast cancer cell will provide us with the necessary tools to successfully 
cure the disease. 
 
1.11 Hypotheses and Aims 
Aim 1: To decipher the genomics impact of FOXA1 and GATA3 in modulating ERα 
action 
In our previous (Lin et al, 2007) and recent (Joseph et al, 2010) studies, we have 
identified high confidence ERα binding sites in MCF-7 human mammary carcinoma cells. 
With known motif scanning and de novo motif finding methods, we identified that 
FOXA1 and GATA3 motifs were commonly enriched within ERα binding sites. 
Moreover, numerous microarray studies have documented the co-expression of ERα, 
FOXA1 and GATA3 in primary breast tumors (Badve et al, 2007; Wilson et al, 2008). 
Though this evidence suggests that these three TFs, ERα, FOXA1, and GATA3 may 
cluster on DNA binding sites and involved in the breast cancer phenotype, there is little 
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understanding as to the nature of their coordinated interaction at the genome level or the 
biological consequences of that detailed interaction.   
To address this gap of knowledge, we aim to investigate the ERα-mediated 
transcriptional networks orchestrated with FOXA1 and GATA3 in breast cancer cells. 
We will use chromatin immunoprecipitation-sequencing (ChIP-seq) to define the binding 
profiles of ERα, FOXA1, and GATA3 as to study the interplay among these TFs in breast 
cancer cells. Specifically, we wish to dissect the roles of FOXA1 and GATA3 in 
regulating ERα action; to study the progressive recruitment of these TFs to the cis-
regulatory elements; and to map the genomic effects of ERα, FOXA1 and GATA3 in 
altering the transcriptional activation in breast cancer cells.  
 
Aim 2: To investigate the biological consequences by the conjoint action of ERα, 
FOXA1 and GATA3 in breast cancer cells 
ERα is known as a ligand-activated TF that mediates the proliferative effects of estrogen 
in breast cancer cells. However, some physiologic and cellular contradictions have been 
previously noted in ERα biology. Garcia et al (Garcia et al, 1992) showed that the 
transfection of the ER alone into ERα negative cell lines has commonly no growth 
effect or even represses growth. This is also true for an important ERα associated TF, 
FOXA1, where introduction of this gene represses cell growth (Wolf et al, 2007).   
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We posited that these higher order regulatory mechanisms of ERα function such as the 
formation and composition of enhanceosomes may explain the establishment of 
transcriptional regulatory cassettes favoring either growth enhancement or growth 
repression.  As such, we hypothesized that the absence of critical co-regulating TFs such 
as FOXA1 and GATA3 in the ERα-negative breast cancer cells has resulted inhibited 
growth in the ERα-negative breast cancer line.  
To resolve this, we aim to determine if FOXA1 and GATA3 are essential components of 
ERα-induced proliferation in breast cancer cells in response to estrogen stimulation.  
 
Aim 3: To study the estrogen-responsive cassettes that drive the growth and 
proliferation of breast cancer cells 
Currently, the most effective therapy in tackling the ERα-positive breast tumors is by 
interrupting the estrogen-dependent functions in proliferation and survival. Therefore, the 
discovery of any agent that would influence the growth and proliferation of the breast 
cancer cells would allow us to gain momentous understanding in the estrogen-responsive 
growth and ultimately could aid in containing this disease. This motivates us to 
investigate the estrogen-responsive cassettes that drive the growth and proliferation of 
breast cancer cells.  
To achieve this, we aim to study how the presence of ERα, FOXA1 and GATA3 can 
orchestrate the symphony of estrogen-inducible growth by evaluating the gene expression 
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and ERα binding profile of the proliferating estrogen-responsive breast cancer cells. This 






















CHAPTER 2: MATERIALS AND METHODS 
 
2.1 Cell Culture 
The MCF-7, BT-549 and MDA-MB-231 cells were obtained from American Type 
Culture Collection (ATCC; Rockville MD, USA). The MCF-7 and BT-549 cells were 
maintained in phenol-red DMEM media supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin streptomycin (Invitrogen, CA, USA). The MDA-MB-231 cells 
were grown in RPMI media supplemented with 10% FBS and 1% penicillin streptomycin. 
The cells were maintained in 37˚C incubator buffered with 5% carbon dioxide (CO2) 
where the sub-culturing was performed twice a week using 0.05% Trypsin-EDTA 
(Invitrogen, CA, USA). The DMEM and RPMI media were purchased from the Biopolis 
Shared Facilities (BSF), Singapore. 
 
2.2 Chromatin Immunoprecipitation (ChIP) Assay 
The MCF-7 cells were grown to approximately 70% confluent before subjecting to ChIP 
assay. The phenol-red growth media was removed from the cells, followed by three times 
phosphate buffered saline (PBS) washes for complete removal of phenol-red media 
before subjecting to the phenol-red free media supplemented with 5% charcoal-dextran 
treated FBS (CDFBS; HyClone, Utah, USA).  The serum-depleted MCF-7 cells were 
treated with 10nM E2 (Sigma-Aldrich, St Louis, USA) or vehicle control for 45 minutes. 
Cells were crosslinked with 1% formaldehyde (Sigma-Aldrich, St Louis, USA) for 10 
minutes at room temperature, followed by 125mM glycine (Sigma-Aldrich, St Louis, 
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USA)   treatment for 5 minutes at room temperature to inactivate the crosslinking. The 
cells were washed with cold phosphate buffered saline (PBS) twice to remove traces of 
formaldehyde before subjecting to trypsination. The cells were collected from the culture 
dish using the cell scrapper. The cells were pelleted by refrigerated centrifugation at 
3,000 rpm for 5 minutes. The nuclear lysates were collected after three rounds of 
incubation in Triton-X lysis buffer (0.25% Triton X-100, 10mM EDTA, 10mM Tris-HCl 
at pH 8, 10mM NaCl and 1X protease inhibitor) with gentle rotation at 4˚C for 10 
minutes.  The chromatin extracts were fragmentized to an average size of 500bp with 
sonication using Branson digital sonifier (Branson Ultrasonics, CT, USA) in the SDS 
lysis buffer (1% SDS, 5mM EDTA, 50mM Tris-HCl at pH 8 and 1X protease inhibitor). 
The sepharose G-beads (Invitrogen, CA, USA) was blocked with bovine serum albumin 
(BSA; Sigma-Aldrich, St Louis, USA) for 2 hours at 4˚C. The chromatin extracts were 
pre-cleared with the BSA-blocked sepharose beads for 2 hours at 4˚C followed by 
overnight immunoprecipitation in dilution buffer (1% Triton X-100, 2mM EDTA, 20mM 
Tris-HCl at pH 8, 150mM NaCl and 1X protease inhibitor) added with the ChIP antibody 
at 4˚C. An aliquot of pre-cleared chromatin was used as the input control. The 
immunoprecipitated beads were washed with TSE I buffer (0.1% NP-40, 1% Triton X-
100, 2mM EDTA, 20mM Tris-HCl at pH 8 and 150mM NaCl) , buffer III (0.25M LiCl, 1%
NP-40, 1% deoxycholate, 1mM EDTA and 10mM Tris-HCl at pH 8)  and TE wash 
buffer (2mM EDTA and 10mM Tris-HCl at pH 8) at 4˚C for 10 minutes followed by 
elution (1% SDS, 10mM EDTA and 50mM Tris-HCl at pH 8) at 65˚C for 30 minutes 
with mixing at 800rpm in the Thermomixer (Eppendorf, Hamburg, Germany). The 
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protein-DNA complex was subjected to 2 hours pronase (Roche, Mannheim, Germany) 
treatment at 42˚C followed by de-crosslinked with overnight incubation at 65°C. DNA 
extraction was performed using phenol/ chloroform (Ambion, Texas, USA) for organic 
phase separation followed by precipitation with cold ethanol, sodium acetate (Ambion, 
TX, USA) and GlycolBlue (Invitrogen, CA, USA) as the carrier. The precipitated ChIP 
and input DNA was measured using pico green quantification (Invitrogen, CA, USA).  
The quantitative PCR (qPCR) validation was carried out using SYBR Green chemistry on 
ABI7900 platform (Applied Biosystems, CA, USA). The ChIP samples were then 
subjected to ChIP-sequencing on Solexa platform (Illumina, CA, USA).  
 
2.3 Preparation of ChIP samples for solexa sequencing. 
This protocol describes the preparation of libraries of chromatin-immunoprecipitated 
DNA using the ChIP-seq Sample Preparation Kit (Illumina, CA, USA) in a format 
compatible with the Illumina’s cluster amplification and sequencing platforms. The 
objective of the protocol is to add adapter sequences onto the ends of DNA fragments to 




The ‘Adapter 1’ and ‘Adapter 2’ sequences correspond to the two surface-bound 
amplification primers on the flowcells used in the cluster amplification platform, and the 
‘Sequencing primer’ corresponds to the primer used in the sequencing reaction.  
Adapter 1 Sequencing Primer ChIP DNA fragments Adapter 2 
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The ChIP DNA was end-repaired with T4 DNA polymerase, T4 polynucleotide kinase 
(PNK) and Klenow enzyme. The exonuclease activity of these enzymes removes 3’ 
overhangs and the polymerase activity fills in the 5’ overhangs. This followed by the 
purification on the QIAquick column using the QIAquick PCR Purification Kit (Qiagen).  
An ‘A’ base was added to the 3’ end of the blunt phosphorylated DNA fragments using 
the polymerase activity of Klenow fragment (3’ to 5’ exo minus). This prepared the DNA 
fragments for ligation to the adapters which have a single ‘T’ base overhang at their 3’ 
end.  
The ‘Adapter 1’ and ‘Adapter 2’ were ligated to the ends of the DNA fragments using 
DNA ligase to prepare the hybridization of DNA fragments to the flow cell.  The adapter-
modified DNA fragments were amplified using Pfx polymerase (Invitrogen, CA, USA) in 
thermacycler machine. The unligated adapater was removed from the amplified DNA by 
semi-size selection of 200-300bp by the gel electrophoresis on the 2% Ultra low-range 
agarose gel (Bio-Rad Laboratories, CA, USA) followed by 30mins staining with SYBR 
Green I Nucleic Acid Gel stain (Invitrogen, CA, USA). The DNA-gel extraction was 
performed using the Gel Extraction Kit (Qiagen GmbH, Hilden, Germany). The selected 
DNA fragments were quantified using the DNA 1000 Chip on the Bioanalyzer (Agilent 
Technologies, CA, USA). The verified DNA fragments were then submitted to 






2.4 Gel extraction 
The agarose gel was visualized using the UV illuminator, the fragment size ranged from 
200-300bp was excised using a sterile blade and placed into a 15ml Falcon tube. The 
excised gel was weighed and the gel extraction was performed using the Qiagen Gel 
Extraction Kit (Qiagen GmbH, Hilden, Germany). Three volume of QG buffer was added 
into the excised gel and incubated at room temperature for 10 minutes until the gel was 
completely dissolved. One gel volume of isopropanol (Sigma-Aldrich, St Louis, USA) 
was added to the dissolved sample and mixed thoroughly. The sample was transferred to 
the QIAquick spin column followed by centrifugation at 13,200 rpm for 1 minute at room 
temperature. A total of 750μl PE buffer was added into the column and incubated for 5 
minutes before subjecting to centrifugation at maximum speed for 1 minute. The DNA 
was eluted with EB buffer and quantified using the Agilent DNA 1000 chip. 
 
2.5 Quantification assay on Agilent DNA 1000 chip 
The quantification of DNA fragment was assayed on the Agilent DNA 1000 Chip on the 
Agilent 2100 Bioanalyzer (Agilent Technologies, CA, USA). The gel-dye mix was 
equilibrated to room temperature for 30 minutes in the dark before loading into the 
Agilent DNA 1000 Chip. The chip was primed on the priming station for 1 minute using 
the 1ml syringe. The DNA ladder, DNA marker and DNA samples were loaded into the 
respective wells. The DNA Chip was vortexed for 1 minute at 2,400 rpm before loading 




2.6 Antibodies used in this study 
Antibody Catalog 
number 
Supplier Application Concentration 
ERα Sc-543 Santa Cruz 




FOXA1 AB-4124 Chemicon, MA, USA ChIP 5μg 
FOXA1 Ab-5089 Abcam, Cambridge, UK Western blot 1:500 
GATA3 Sc-22205X Santa Cruz 
Biotechnology, CA, USA 
ChIP 5μg 
GATA3 Sc-269 Santa Cruz 
Biotechnology, CA, USA 
Western blot 1:500 
RNA pol II Ab-5408 Abcam, Cambridge, UK ChIP 5μg 
p300 Sc-584X Santa Cruz 
Biotechnology, CA, USA 
ChIP 5μg 
Rabbit IgG Sc-2027 Santa Cruz 
Biotechnology, CA, USA 
ChIP 1μg 
Goat IgG Sc-2028 Santa Cruz 




Sc-2004 Santa Cruz 
Biotechnology, CA, USA 
Western blot 1:2000 
Mouse IgG-
HRP 
Sc-2005 Santa Cruz 
Biotechnology, CA, USA 
Western blot 1:2000 
Goat IgG-
HRP 
Sc-2020 Santa Cruz 
Biotechnology, CA, USA 
Western blot 1:2000 
 
Table 1. The list of antibodies used in this study. 
 
2.7 Validation of binding sites identified from the ChIP-seq libraries 
The binding sites were validated with quantitative Polymerase Chain Reaction (qPCR) 
using the specific primer sets. The primers are designed around the binding sites and 
ChIP-qPCR was performed using SYBR Green Chemistry, 1ng of ChIP DNA and 0.5μM 
of primers (listed in Table 2) in the ABI7500 Read-time PCR System (Applied 




No Primer Sequence Coordinates 
1 FX-E1 CCGGTTATCACAGGCTGTTC Chr15: 67674230 
CTGTGTTTGCTCAGCCAATA 
2 FX-E2 ACAATAGCAATCTCAGAGCC Chr20: 46138302 
GAAGGGGAGAGAGTGAATAT 
3 FX-E3 ATAGCAAGTGGCATTTCAAGGC Chr2: 220798228 
AAATGGCAGTGGGAGGTTGG 
4 FX-E4 CTCAAGCAGGTTGTTGAAACTTTGGCTC Chr14: 67393430 
ACATGCCAAACCAGAATAGG 
5 FX-E5 ACAGATCACCAAGAGATAGACC Chr3: 32126930 
GCTGCCCTAAAGTTCCAAGT 
6 FX-E6 GTATTTCAAGACACTCCTGGTG Chr20: 14509472 
TGACCTGACCACCTGCTTAA 
7 FX-E7 AAACGGAGATACAGAGACTGAG Chr9: 12784177 
TTATATTGGCTGCTGCATGG 
8 FX-E8 CCTGTTGTATAACATTGGCC Chr4: 101634844 
CACCTGACCATGTGTACTTA 
9 FX-E9 AGTCAGAATTGGAGGGGAGC Chr21: 42669667 
ATCACTCCTTTTCCTGGCTG 
10 FX-E10 TTGGGGTTGTTTGGTTTCAC Chr13: 25199609 
GCGTTGACAAAAGAGAACAC 
11 FX-E11 AGGGTGAATGAATACCTTATCGGC Chr8: 30403637 
CCTCAGCCTGTTCAATGCCTTTAAGA 
12 FX-E12 ATTGTACCTTCAAAGTGCCAGG Chr3: 158013191 
TAGATGAGCCCCAACAGGACCT 
13 FX-E13 AAGAGGCACTGATCTACCAG Chr11: 
131272536 GTGTGATGACATTTAACTCC 
14 FX-E14 GAATGATGACAAGGTCCCTC Chr3: 194019535 
GGCAGTTCAGATTCTAGCAA 
15 FX-E15 AATTCTCCAAGACCAAGGTG Chr22: 17535957 
GATGGCTCTATTCAGATCCC 
16 FX-E16 AGACCTAATGTCTCTAGGACCTAATGGC Chr8: 29641276 
GGAAAGAGCCACACGAATGTAA 
17 FX-E17 TCCAGGATGACTCATGTGGC Chr4: 129602041 
CAAGCCATAAAGCCACACGT 
18 FX-E18 GACGGCTTTCAGATTGTGCTAC Chr17: 23888137 
ATGTGCTGGGAACAGAGCCT 
















23 FX-V1 ATCACAGGCTGTTCTAATGC Chr15: 67674230 
CTGTGTTTGCTCAGCCAATA 
24 FX-V2 TATCCAGAGGTTAGTTGTAGGC Chr17: 56788982 
CAGAAAGGGCTAGAAGAACA 
25 FX-V3 CTACATTTGAAAACAACTGCCCTGCC Chr20: 39712749 
GTGGAAGTTCTAGCTGTGCA 
26 FX-V4 TCATGTTGCCTGTTCCTTAC Chr1: 112321182 
CTGCATCTCAACAAGGAATC 
27 FX-V5 TTGGGGACATCCAAGTTGTTTCCAG Chr1: 230366909 
GCTGACAGACATTCCGCTAGTCACTAAGTA 
28 FX-V6 TCCTACTACCAACACTTGTG Chr8: 19789795 
TACCTCCATCTCTCTGGTAC 
29 FX-V7 AAAATCTGCATTCCAGGAGC Chr12: 25568826 
CCACTCTGTAAACCAGTTTGTG 
30 FX-V8 CAGGGAGCCAGCATTCTAGCAAAG Chr19: 47100617 
AAGACACGCCTCTGTGCAAACACCTG 
31 FX-V9 TTAGGCAAGAGTCATCAGTG Chr11: 76327997 
CCAGATTTCCCCACTGTTAA 
32 FX-V10 CTGAGGATATTTACCAAGGC Chr5: 11787705 
CCTGGAGGGATGTGTAATGTAA 
33 FX-V11 CTGGTCTTGTTTATAGAGCC Chr7: 108041502 
TCAGGTGGAATGAGATCATG 
34 FX-V12 GGTCTTACGTTGAGGAATGG Chr3: 53527983 
GCGAAGTGGTAAAGCTGTTTGT 
35 FX-V13 ATCAAAGGGGTCAGAGGCTG Chr7: 101130618 
CAGAGAGGGTGGATGACATG 
36 FX-V14 AAGACATCCACTGGGAAAGC Chr6: 11385547 
AGTAGAGGCAGAAACCCTTT 
37 FX-V15 CAGCTTGGTGGTTTCTTCTAC Chr9: 139496534 
TGGACAGAGGTTTTCAGTTC 
38 FX-V16 CTTGTCTCAAAGGCGGAAGG Chr6: 144241402 
CTCCTTAGGGCAAATCACAG 




40 FX-V18 TTTTGCCAGGGTTAATGATGTGCC Chr13: 68158339 
GATGTCTCATGTCACCCTAA 












CACTATTGCTCATCTCTGGAG chr3: 62880069 
ATCTTTTGCCTGAGCTACCC 
45 GATA3-E1 GAAATCCTTAGAACCAGAGC Chr11: 1774487 
CATCTTCCAGTGTGGCTAAG 
46 GATA3-E2 ACTCTGGATAGCCTTGGAGG Chr1: 117613263 
CTGTTCCTGGAAGGATGTTT 
47 GATA3-E3 CCCAGTGGTGTTGACATTCAG Chr7: 80344311 
GGCTGACTCAGAAGCAAACTGTAGAA 
48 GATA3-E4 GCAACGCCACCTTGACATTC Chr20: 48814298 
TGCAAAACAGCCACACAAAC 
49 GATA3-E5 TCTAAAACTGCTCTGTCAGTAAGCGC Chr2: 85340007 
GTTGGGTTTATCGGGCTTTT 
50 GATA3-E6 TGTTTGTGAGCAAAGGAAGG Chr1: 39381340 
GGCCCTCCTGTGTAAGATAG 
51 GATA3-E7 TTCATCAGCATTTGCGAGTG Chr22: 44831270 
TTACAGACACCAGCTTCAGGGC 
52 GATA3-E8 TTTGTGGAGAAATGAGCCTG Chr1: 154853075 
TGCCAACTCAAACAAACAGC 
53 GATA3-E9 GTATCCGCTTGCTTTCCGCATG Chr8: 12961763 
ATGGGACTGCTGATTGCGCCTT 
54 GATA3-E10 CAAAAGAGGATGAGGATGGG Chr4: 38143096 
TCCTGTTTACAAGCACGGCT 
55 GATA3-E11 TCTACTAATGCTCATCACTGCC Chr21: 21541821 
AAAGGAGAAAAGGACGAGGA 
56 GATA3-E12 TTCCCAGCCAGTAATAATCC Chr20: 37062315 
GTGACCAGGAAAGAGCTGCA 
57 GATA3-E13 AAATGAGTGAAGGTCTGTGC Chr22: 23696038 
GGGTCTTCTCTGAAGCCTGT 
58 GATA3-E14 AGGAAGGCAAATGATGTCAC Chr7: 117015702 
TTTCTACTAAGGGACCTCCT 




60 GATA3-E16 TCATCCATTCATTCCCTCAC Chr9: 78632742 
GAGGCAAGGTTATCTCTAGC 
61 GATA3-E17 GAGTGCGGAGTTTATACTTAGACC Chr3: 114775880 
CATCTGCTATGAACTCCCTT 
62 GATA3-E18 TCACTTCAACATCTCAGCTC Chr5: 67358829 
TAGAGATAAGACCAGGCAAG 
63 GATA3-E19 AGTTCTGCTCTTACAGTTCC Chr12: 82903165 
GGAGCTGTAATAGATTGTGC 
64 GATA3-E-




non binding 2 
GTCAACTTCTCTAAGTGTTCTGGG chr6:144494368  
GCTGACAGCTTTCTTACGTT 
66 GATA3-E-
non binding 3 
GGATGTTGTAAGGAATGCTG chr5:136598858  
TCTGAAGGTTTACACTTGCC 
67 GATA3-V1 GGTTGTGTGTGTGTCACTGTCC Chr1: 199545362 
GAGAGCTTCACCGCCAATGC 
68 GATA3-V2 AAATTCCACCCACAAAGCAG Chr10: 9270562 
GGTGAGTTATACAATGAAAGGGCC 
69 GATA3-V3 AAGCTAATAGTTCCCAGAGC Chr9: 136399622 
AAATTACTCTGAGCAGGCAG 
70 GATA3-V4 CTTAGCTTGACAGGCCAGTC Chr5: 73647995 
GTGTAACAGGACCTCACCAT 
71 GATA3-V5 GGAGCAAAGGACATGAACAG Chr7: 122670042 
GCCATTTGGACTTGTATGAG 
72 GATA3-V6 ACCCTGAGATCATTCTTCTG Chr1: 24574381 
CCCAGCAATCACAGGTTTAA 
73 GATA3-V7 CTGGTCACAAGCAGAAATGG Chr22: 27539809 
TTTCCAGTTTGGAGGAGGGA 
74 GATA3-V8 TTACTACATCTTGCCTGCTC Chr3: 99129425 
CCAGGATAAGGTTGGAAAGT 
75 GATA3-V9 TGAATCTGCCTTACTCACGC Chr2: 164658102 
TAGCCTGTGTCAGGTTTGCC 
76 GATA3-V10 CAGTCTCCTTCTGATGCTTAAC Chr5: 36703083 
GCTGTGAGCACTTGAGTCTTAT 
77 GATA3-V11 TCTCAACAGCCCTTTCTAGTTTGC Chr11: 78104621 
TGGGCATCATAGATGCAGCT 
78 GATA3-V12 CCCAAGTCTAACACTAGATC Chr13: 95765479 
GAGTCACTGATTTTCTCCTC 




80 GATA3-V14 ACAGGCTTTCCCTTCTGCAC Chr21: 21391417 
GCTAACTCTTCAGCACATGGAT 
81 GATA3-V15 CTTTATTTAACCTGGCTCCC Chr7: 67424263 
GGCTGTCAAAGAAGGATAAGAG 
82 GATA3-V16 TTACCTCTCCAGCAAAATTCCC Chr6: 10627336 
AGCGCATGAGTCAGCATTTC 
83 GATA3-V17 ACAAATTCCTGTCGCATAGC Chr9: 136808027 
GGCAAGATAAGAGCATTCTCCA 
84 GATA3-V18 TCACTACACTTACCTTCTCACTCACC Chr3: 161194854 
AATCTTGCTTGTTTCCCAGC 
85 GATA3-V19 CTTCCTGTGCAAGGCCAAAC Chr8: 68455991 
CCTTGATAAGCCATCTGAGGAA 
86 GATA3-V-












Table 2. The list of primers used in ChIP-qPCR validation study. 
 
 
2.8 Sequential ChIP (Re-ChIP) 
The ChIP assay was carried out as described previously. The chromatin extracts from the 
first round of immunoprecipitation with ERα antibody was eluted with 10mM DTT (Bio-
Rad Laboratories, CA, USA) at 37˚C for 30 minutes before subjecting to second round of 
immunoprecipitation using FOXA1 and GATA3 respectively. The sequential ChIP using 
IgG was employed as the negative control. qPCR was performed to validate co-
occupancy of ERα+FOXA1 and ERα+GATA3 to the target sites. The primers used for 


































Table 3. List of primers used in the Re-ChIP experiments to investigate the co-occupancy 
of ERα+FOXA1 and ERα+GATA3 to the target sites. 
 
2.9 Cells synchronization 
The MCF-7 cells were grown in phenol-red free DMEM with 5% charcoal dextran-
treated FBS (CDFBS) for 3 days before subjecting to 2.5µM α-amanitin (Sigma-Aldrich, 
CA, USA) treatment for 2 hours. The α-amanitin is able to bind to the large subunit of 
RNA pol II and block the incorporation of new nucleotides into the nascent RNA chain. 
The synchronized cells were verified with cell cycle analysis assay. The cells were 
washed with PBS twice, followed by 10nM E2 or vehicle control treatment for 45 
minutes. Cells were harvested at the 5min interval and subjected to ChIP-qPCR assays. 





















Table 4. List of primers used to study the progressive recruitment of ERα and FOXA1 in 
synchronized MCF-7 cells. 
 
2.10 Cell cycle analysis 
Approximately 1 million synchronized MCF-7 cells were collected by trypsination and 
washed twice with ice-cold PBS. Cells were then fixed with ice-cold 70% ethanol for 5 
minutes at 4˚C and then washed twice in ice-cold PBS. The cells were treated with  
100μg/ml RNase A in PBS (Roche, Manheim, Germany) for 30 minutes at room 
temperature before proceeding to 50μg/ml propidium iodide (Sigma-Aldrich, St Louis, 
USA) stain in dark  for 1 hour at room temperature. The cells were filtered through the 60 
micron membranes to prevent clumping of cells. The DNA content was determined by 
flow cytometry (FACScan flow cytometry system, Becton Dickinson, NJ, USA). The 








2.11 Formaldehyde Assisted Isolation of Regulatory Elements (FAIRE) 
The MCF-7 cells were grown to ~70% confluence in the 150mm culture dish in phenol-
red DMEM media supplemented with 10% FBS. The phenol-red media was removed and 
the cells were washed with 1x PBS three times for complete removal of phenol-red media 
before changing into phenol-red free DMEM supplemented with 5% CD-FBS. The 
serum-depleted cells were grown for 3 days before E2 stimulation. The cells were 
crosslinked with 1% formaldehyde at room temperature for 10 minutes followed by the 
addition of 125mM glycine for 5 minutes to stop the crosslinking. The cells were washed 
with cold PBS twice and the cells were scrapped from the culture dish and pelleted in the 
15ml falcon tube by centrifugation at 3,000 rpm at 4˚C for 5 minutes. The nuclear lysates 
were collected after three rounds of incubation in Triton-X lysis buffer (0.25% Triton X-
100, 10mM EDTA, 10mM Tris-HCl at pH 8, 10mM NaCl and 1X protease inhibitor) 
with gentle rotation at 4˚C for 10 minutes.  The chromatin extracts were fragmentized to 
an average size of 500bp with sonication using Branson digital sonifier (Branson 
Ultrasonics, CT, USA) in the SDS lysis buffer (1% SDS, 5mM EDTA, 50mM Tris-HCl 
at pH 8 and 1X protease inhibitor). Chromatin DNA was extracted using phenol/ 
chloroform (Ambion, TX, USA) twice on the Qiagen MaXtract High Density tube 
(Qiagen GmbH, Hilden, Germany) for phase separation and precipitated using ethanol 
(Sigma-Aldrich, St Louis, USA), sodium acetate (Ambion, TX, USA) and GlycolBlue 
(Invitrogen, CA, USA) as the carrier. The precipitated DNA was washed with 70% 




2.12 DNA quantification using PicoGreen 
The quantification of DNA was performed using Quan-iT PicoGreen dsDNA Assay Kit 
(Invitrogen, CA, USA). Serial dilutions of the Lambda DNA (100μg/ml) ranged from 2.5 
pg/μl to 0.1 ng/μl in TE buffer (10mM Tris HCl and 1mM EDTA) were prepared and 
added with 1x PicoGreen to generate a standard curve for DNA quantification. The 
samples were excited at 480nm and fluorescence emission intensity was measured at 
520nm using Sunrise microplate reader (Tecan, Männedorf , Switzerland). 
 
2.13 RNA extraction from MCF-7, MDA-MB-231 and BT-549 cells  
The RNA extraction was performed by incorporating the use of TRIzol reagent 
(Invitrogen, CA, USA) and RNeasy Mini Kit (Qiagen, Hilden, Germany) for maximum 
RNA yield and minimal contamination. The cells were washed with cold PBS twice 
before subjecting to cell lysis with 1ml of TRIzol reagent. A total of 0.2ml chloroform 
(Sigma-Aldrich, St Louis, USA) was added followed by vigorous shaking for 15 seconds 
and a room temperature incubation of 3 minutes before subjecting to centrifugation at 
13,200 rpm for 15 minutes at 4˚C. The upper aqueous phase was transferred to a fresh 
1.5ml tube and 1 volume of 70% ethanol (Sigma-Aldrich, St Louis, USA) was added and 
mixed well. The sample was then transferred into an RNeasy spin column and 
centrifuged at maximum speed for 1 minute. This followed by centrifugation with the 
RW1 and RPE buffers. The sample was eluted in RNase-free water and the RNA 




2.14 Microarray gene expression study on the MCF-7 cells 
The MCF-7 cells were grown in phenol-red free DMEM with 5% CDFBS for 3 days 
before E2 stimulation. Total RNA was harvested at 3, 6, 9, 12, 24 and 48-hour after E2 
treatment using TRIzol (Invitrogen, CA, USA) and RNeasy Mini Kit (Qiagen GmbH, 
Hilden, Germany). The quality of RNA samples was verified with Agilent 2100 
Bioanalyzer (Agilent Technologies, CA, USA) before proceeding to Affymetrix 
microarray experiments on the HG-U133 Plus 2.0 Chip (Affymetrix, CA, USA). The 
samples were labeled with GeneChip Eukaryotic One-cycle Target Labeling Kit 
(Affymetrix, CA, USA). The first strand of cDNA synthesis was performed on 1μg of 
total RNA using oligo dT and SuperScript II (Invitrogen, CA, USA). The IVT labeling 
was performed at 37˚C overnight followed by cRNA fragmentation at 94˚C for 35 mins 
and hybridization at the GeneChip Hybridization Oven 640 (Affymetrix, CA, USA) at 
45˚C for 16 hours. The GeneChip array was subjected to various washing steps using the 
GeneChip Fluidics Station 450 (Affymetrix, CA, USA) and scanned with GeneChip 
Scanner 3000 (Affymetrix, CA, USA).  
 
2.15 Microarray gene expression study on the transfected MDA-MB-231 and BT-
549 Cells 
The transfected MDA-MB-231 and BT-549 cells were grown in phenol-red free RPMI 
and DMEM supplemented with 5% CDFBS and selection marker G418 respectively 
before subjecting to E2 stimulation. Total RNA was harvested at 6-hour, day 2 and day 10 
using TRIzol (Invitrogen, CA, USA) and RNeasy Mini Kit (Qiagen GmbH, Hilden, 
60 
 





 Biotin-aRNA Labeling Kit (Epicentre Biotechnologies, MA, 
USA). The Poly(A) RNA was reverse transcribed into first-strand cDNA using the oligo 
dT primer and SuperScript III Reverse Transcriptase (Invitrogen, CA, USA). The 
cDNA:RNA hyrid that was produced during the first strand cDNA synthesis step was 
converted into double-stranded cDNA containing a T7 transcription promoter followed 
by the biotin-labeling at 42˚C for 4 hours in a thermocycler (Bio-Rad Laboratories, CA, 
USA). The sample was then purified using Qiagen RNease Mini Kit (Qiagen GmbH, 
Hilden, Germany). An equal amount of 750ng RNA was hybridized on the Human HT-
12 v4 Expression BeadChip (Illumina, CA, USA) at 58˚C for 16 hours. The BeadChip 
was then subjected to several washes with E1BC buffer, blocked with E1 Block buffer, 
stained with streptavidin-Cy3 and scanned on the BeadArray Reader (Illumina, CA, 
USA). 
 
2.16 Cloning experiment 
A linearized pGL4-luciferase vector was generated using SacI and HindIII (New England 
Biolabs, MA, USA) digestion. The promoter region with the co-occupancy of ERα, 
FOXA1 and GATA3 bindings at the GREB1 gene (coordinate - chr2:11588510-
11588910) was cloned into pGL4-luciferase construct using the In-Fusion HD Cloning 
kit (Clontech Laboratories, CA, USA). The In-Fusion PCR primers were designed in a 
manner that generates PCR products containing ends that are homologous to the vector. 
The In-Fusion cloning reaction was performed at 50˚C for 15 minutes using the genomic 
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DNA extracted from the MCF-7 cells and In-Fusion HD Enzyme Premix. The cloned 
product was verified with sequencing and stored at -20˚C until it is ready for 
transformation. The In-Fusion PCR primers used are as follows (pGL4-luciferase vector 
sequences were underlined): 
GREB1 forward primer: CCGGTACCTGAGCTCGCCAGAGAAGCCCTTTGTAC  
GREB1 reverse primer: CGGATTGCCAAGCTTAAATGCTGGAGTCGCACCAA  
 
2.17 Site-directed mutagenesis assay 
The in vitro mutagenesis assay was performed using the QuikChange Site-Directed 
Mutagenesis Kit (Stratagene, CA, USA) with high fidelity PfuTurbo DNA polymerase.  
Several oligonucleotide primers containing the mutated ERα, FOXA1, and GATA3 
binding motifs were designed (1
st
 BASE, Singapore). The incorporation of mutagenesis 
primers generates a mutated plasmid. Following thermocycler (Bio-Rad Laboratories, CA, 
USA) amplification, the product was treated with Dpn I endonuclease to digest the non-
mutated parental DNA. The vector DNA containing the desired mutation was stored at -
20˚C until it is ready for transformation. The sequences of the GREB1-luc construct as 
well as the mutated-luc constructs were verified with sequencing (1
st
 BASE, Singapore).  
The mutagenesis primers with the underlined point mutation are listed as follows: 














Table 5. The list of mutagenesis primers. 
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2.18 Chemical transformation experiment 
A tube of frozen One Shot Top10 chemically competent cells (Invitrogen, CA, USA) was 
removed from the -80˚C freezer and placed on ice. Approximately 5μl of the cloned DNA 
was added into the competent cells and mixed by flicking the tube gently. The tube was 
placed on ice for at least 30 minutes before heat shock for 30 seconds in the 42˚C 
waterbath. The tube was placed immediately on ice for 2-5 minutes before adding 500μl 
of SOC medium (Invitrogen, CA, USA) and incubated for 1 hour at 37˚C with shaking at 
250rpm. The cells was pelleted by centrifugation at 3000rpm for 5 minutes and then 
resuspended in 100μl of SOC medium and plated on the pre-warmed LB plates added 
with ampicillin. The plate was incubated at 37˚C for 16 hours. A single bacterial colony 
was picked and inoculated in lysogeny broth (LB) to extract the plasmid DNA for 
downstream work. 
 
2.19 Expression clones 
The expression clones encoding human ESR1, FOXA1 and GATA3 were purchased from 
GeneCopoeia (MD, USA). Transformation experiment was performed using these 
expression clones. After verification with agarose gel electrophoresis (Bio-Rad 
Laboratories, CA, USA) and sequencing analysis, the plasmid DNA were expanded and 
purified with Plasmid Maxi Kit (Qiagen GmbH, Hilden, Germany). The plasmid DNA 




2.20 Western blot  
The nuclear lysate was extracted using SDS lysis buffer (1% SDS, 5mM EDTA, 50mM 
Tris-HCl at pH 8 and 1X protease inhibitor). Equal amounts of protein were mixed with 
2x Laemelli loading buffer (Bio-Rad Laboratories, CA, USA) and boiled for 5 minutes. 
The samples were then separated by sodium dodecyl sulfate (10%) polyacrylamide gel 
electrophoresis gels (SDS-PAGE; Bio-Rad Laboratories, CA, USA) and transferred to 
nitrocellulose membrane (Bio-Rad Laboratories, CA, USA). The membrane was blocked 
with 5% non-fat milk (Bio-Rad Laboratories, CA, USA) in Tris-buffered saline (1
st
 
BASE, Singapore) containing 0.1% Tween 20 (TBST; Sigma-Aldrich, St Louis, USA) at 
room temperature for 1 hour. The membrane was washed twice with TBST to remove 
excess milk and membrane was incubated with the relevant primary antibody in TBST 
with 5% non-fat milk at 4˚C overnight. The membrane was subjected to four washes with 
TBST to remove unbound primary antibody prior to incubation with the appropriate 
HRP-conjugated secondary antibody for 1 hour at room temperature. The membrane was 
washed four times using TBST to remove excess unbound secondary antibody. The 
detection for the protein of interest was performed using ECL Prime Western Blotting 
Detection Reagent (GE, UK) and Kodak Biomax X-ray film (Kodak, NY, USA).  
 
2.21 Transfection experiments 
The MDA-MB-231 and BT-549 cells were stably transfected with ERα, FOXA1, and 
GATA3 using Lipofectamine 2000 (Invitrogen, CA, USA) according to the 
manufacturer’s instructions. The cells were seeded into 6-well plates one day before 
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transfection experiment so the cells can reach ~90% confluent at the time of transfection. 
A total of 2μg of plasmid DNA and 6μl Lipofectamine 2000 at the ratio of 1:3 was 
diluted and mixed gently in Opti-MEM Medium (Invitrogen, CA, USA) without serum 
respectively. After the 5 minutes incubation at room temperature, the diluted plasmid 
DNA and Lipofectamine 2000 were combined and incubated at room temperature for 20 
minutes. The mixture of plasmid DNA and Lipofectamine 2000 was added into the cells 
and rocked gently. The cells were incubated in a 37˚C CO2 incubator with a medium 
change after 6 hours. The cells were passaged into 10cm culture dish 24 hours after 
transfection. The selective antibiotic, Geneticin (G418; Invitrogen, CA, USA) was added 
into the medium the following day. An empty vector transfection was included as a 
negative control. The G418-selected clonal cells were verified for their ERα, FOXA1, 
and GATA3 expression using western blot. 
 
2.22 Luciferase Reporter Assays 
The MDA-MB-231 cells were transfected with the reporter construct together with 
different combination of TFs. The MCF-7 cells were transfected with the reporter 
construct together with the mutated ERα, FOXA1 and GATA3 constructs. A Renilla 
luciferase plasmid was co-transfected as an internal control. Dual-Luciferase Reporter 
Assay System (Promega, WI, USA) was employed to measure the relative Renilla 
activity according to the manufacturer’s instructions. The growth media was removed 
from the cells and rinsed with 1x PBS. The cells were lysed with 1x PLB and rocked at 
room temperature for 15 minutes. The Luciferase Assay Reagent was added into each 
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sample and the light intensity produced was measured using GloMax 96 Microplate 
Luminometer (Promega, WI, USA). 
 
2.23 Cell proliferation WST-1 assay 
The transfected MDA-MB-231 and BT-549 cells were seeded in 96-well plate and 
subjected to 10nM E2 or vehicle treatment. The culture media was changed every 3 days 
and the cell proliferation was assayed with Cell Proliferation Reagent WST-1 (Roche, 
Manheim, Germany). A total of 10μl Cell Proliferation Reagent WST-1 was added into 
the cells cultured in 100μl/well (1:10 final dilution). The cells were incubated at 37˚C 
incubator in dark for 1 hour before proceeding to measurement with Sunrise Microplate 
Absorbance Reader system (Tecan, Männedorf, Switzerland). A blank with the same 
volume of culture medium and Cell Proliferation Reagent WST-1 was recruited as the 
background control.  
 
2.24 Cell proliferation with cell count assay 
Another cell growth assay assessed by cell number count was performed. The cells are 
fixed with 2% paraformaldehyde (Sigma-Aldich, St Louis, USA) and incubated at room 
temperature for 45 minutes. The cells were washed with 1x PBS three times before 
permeabilization with 0.1% Triton-X (Bio-Rad Laboratories, CA, USA) at room 
temperature for 10 minutes. The cells were washed with 1x PBS three times followed by 
Hoechst staining (2.5μg/ml) in dark at room temperature for 10 minutes. The number of 
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cells were counted using Cellomics ArrayScan VTi machine (Thermo Fisher Scientific, 
DE, USA).   
 
2.25 Short reads mapping 
The reads of 25 bp from each library were mapped independently to the reference 
genome hg18 using the BatMan package (Tennakoon et al, manuscript in preparation). 
BatMan is a Burrows-Wheeler-Transform-based (BWT) method which maps short 
sequences to a reference genome at a very high speed.  
Up to 2 bp mismatches were allowed. The non-mappable reads and reads with more than 
2 "best mapping" genomic locations were removed. The best mapping means, if a read 
has mapping locations without mis-match (as 0 mis-match), the best mapping will be the 
locations without mis-match; if a read has no mapping location with 0 mis-match, the 
mapping locations with 1 mis-match will be the best mapping locations; and the same for 
2 mis-matches, etc. Only the best unique mapped location for each mappable read was 
kept for further processing. 
 
2.26 Binding sites analysis 
The short reads from ChIP-seq libraries were aligned to the human genome hg18 using 
Batman with at most 2 mismatches, and only the uniquely mapped reads were extracted 
for further analysis. Here, we used the  Model based Analysis for ChIP-Seq (MACS) to 
call the peaks for all the three TFs (Zhang et al, 2008) with default parameters. The peaks 
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were reported as the summit of the enriched regions. The overlap of peaks from two 
libraries is defined as the peaks within genomic distance 200bp. 
 
 





MCF-7 ERα-45 min E2 19412 8.0 millions 
MCF-7 ERα-45 min vehicle 1990 13.6 millions 
MCF-7 FOXA1-45 min E2 15852 13.5 millions 
MCF-7 FOXA1-45 min 
vehicle 
9337 19.6 millions 
MCF-7 GATA3-45 min E2 38530 23.6 millions 
MCF-7 GATA3-45 min 
vehicle 
20707 16.8 millions 
MCF-7 RNA pol II-45 min 
E2 
Not applicable 7.6 millions 
MCF-7 RNA pol II-45 min 
vehicle 
Not applicable 9.6 millions 
MCF-7 P300-45 min E2 Not applicable 12.8 millions 
MCF-7 P300-45 min 
vehicle 
Not applicable 16.9 millions 
MCF-7 FAIRE-45 min E2 Not applicable 12.6 millions 
MCF-7 FAIRE-45 min 
vehicle 
Not applicable 12.3 millions 
MDA-MB-231+ER ERα-45 min E2 934 13.2 millions 
MDA-MB-231+ER ERα-Day 10 E2 940 14.4 millions 
MDA-MB-
231+ER+FOXA1+GATA3 
ERα-45 min E2 2666 11.0 millions 
MDA-MB-
231+ER+FOXA1+GATA3 
ERα-Day 10 E2 3777 9.8 millions 
BT-549+ER ERα-45 min E2 2465 44.1 millions 
BT-549+ER ERα-Day 10 E2 1544 43.2 millions 
BT-549+ER+FOXA1+GATA3 ERα-45 min E2 2962 49.6 millions 
BT-549+ER+FOXA1+GATA3 ERα-Day 10 E2 4284 44.0 millions 
Table 6. The tabulation for the number of reads and binding sites from all the ChIP-seq 
libraries used in this study. 
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2.27 Fold change of the numbers of binding sites before and after E2 treatment 
As shown in Table 6, there may be concerns that the sequencing depth of the library has 
some effects on the number of binding sites. To minimize the effect of the sequencing 
depth on the fold change of the numbers of binding sites before and after E2 treatment, 
we normalized the fold change of the numbers of binding sites with the sequencing depth. 
Using ERα library as an example, the sequencing depths are 13.6 million reads before E2 
treatment and 8 million reads after E2 treatment. There are 1990 binding sites before E2 
treatment and 19412 binding sites after E2 treatment. We computed the fold change of the 
numbers of binding sites as follows: 
 
                                                      
     
    
 
    
       
 
 
2.28 Motif analysis 
The motif scanning was done with the program CentDist (Zhang et al, 2011) with motif 







2.29 Association of Transcription Factor Binding with Gene Expression 
The binding sites were associated with the nearest transcription start sites within 20kb. In 
order to assign peaks to genes, we look for the nearest transcription start site (TSS) from 
the Genome Browser by University of California Santa Cruz (UCSC) RefSeq genes for 
each peak. If the distance from the peak to the nearest TSS is less than 20kb, the peak 
will be assigned to the TSS. In this way, each peak is assigned to at most one TSS. 
However, each TSS may have a few peaks assigned from the same TF. If a TSS is the 
nearest TSS to at least one ERα peak, we will associate this TSS to the ERα peak, 
regardless of the number of possible ERα peaks within the distance of 20kb. Similarly, 
the same TSS can be associated to FOXA1 and GATA3 peaks. Based on the condition 
whether the TSS is associated with ERα, FOXA1 and GATA3 peaks, the TSS will be 
grouped into 8 different categories: 1) with ERα+FOXA1+GATA3 peaks; 2) with 
ERα+FOXA1 peaks; 3) with ERα+GATA3 peaks; 4) with FOXA1+GATA3 peaks; 5) 
with ERα peaks only; 6) with FOXA1 peaks only; 7) with GATA3 peaks only; and 8) 
without any peaks.  
For the category with ERα+FOXA1+GATA3 peaks, the situation can be sub-divided into 
two sub-categories with/without ERα+FOXA1+GATA3 conjoint peaks as shown  in the 
following illustrations. In the left figure, we associated the TSS with 
ERα+FOXA1+GATA3 non-overlapped peaks. In the right figure, we associated the TSS 





Figure 20. These illustrations demonstrated the two different scenarios where the 
ERα+FOXA1+GATA3 peaks were associated with the TSS. 
 
 
2.30 Analysis of the gene expression profiles of MCF-7, MDA-MB-231 and BT-549 
transfectant cells 
We have three different MDA-MB-231 and BT-549 transfectant cells: transfected with 
vector control, ERα-only, and ERα+FOXA1+GATA3. These different transfectants were 
subjected to estrogen and vehicle treatment, the cells were collected at day 2 and day 10 
before proceeding to microarray experiment performed on 3 biological replicates.   
The gene expression was calculated in the following procedure. The expression of the 
probes is measured by the fold change of the raw intensities from E2 treatment over the 
raw intensities from vehicle treatment, and followed by median-normalization in each 
replicate. The normalized expression from the probes was averaged from three replicates. 
The expression of the probes from the same genes was averaged to generate the final 
expression level of the genes. The genes with fold change over 1.2 (which corresponds to 
0.263 after log2 transformation) are called as up-regulated genes, and the genes with fold 
change lower than 0.83 are called as down-regulated genes. The E2-regulated genes from 
the vector-control MDA-MB-231/ BT-549 cells, ERα-expressing MDA-MB-231/ BT-
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549 cells and ERα+FOXA1+GATA3-expressing MDA-MB-231/ BT-549 cells are 
overlapped with the E2-regulated genes from MCF-7, and this list of genes are used to 
compare the expression from different cells. 
For the comparison of MDA-MB-231/ BT-549 transfectants and MCF-7, we used a 
growth normalized strategy.  This means that the time points that are compared are 
selected by the time of equivalent phenotype.  This strategy was used in defining MYC 
effects on apoptosis where different conditions gave the same gene responses but with 
different phasing (Yu Q. et al, 2002).  In our experimental case, we found that MDA-
MB-231/ BT-549-ERα+FOXA1+GATA3 triple transfectant exhibited E2 stimulated 
growth only after day 7 and maximally by day 10.  By contrast, MCF-7 showed near 
optimal growth induction after 24 hours of E2 exposure.  Therefore, our array comparison 
was between the 24 hours time-point for MCF-7 and 10 days for MDA-MB-231/ BT-
549- ERα+FOXA1+GATA3. 
 
2.31 Analysis on the Expression Levels of Luminal and Basal Marker Genes  
Based on the recently published luminal and basal marker gene list from Kao et al (Kao 
et al, 2009), we included 45 luminal marker genes and 49 basal marker genes (referred to 
as the luminal/basal cassette) that are present in both our MCF-7 and transfected MDA-
MB-231/ BT-549 expression data. We generated the box plots for the expression levels of 
these luminal and basal marker genes in the MCF-7 and transfected MDA-MB-231/ BT-
549 cells after estrogen stimulation. Additionally, we assessed the expression changes of 
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the luminal/basal cassette from MDA-MB-231/ BT-549 cells transfected with vector 
control to the MDA-MB-231/ BT-549 cells transfected with ERα+FOXA1+GATA3. The 
expression level of a gene from the MDA-MB-231/ BT-549 cells transfected with 
ERα+FOXA1+GATA3 was deducted with the expression level of the same gene from the 
MDA-MB-231/ BT-549 cells transfected with vector control.  
 
2.32 Genome-wide co-motif analysis using Pomoda 
Peak Oriented Motif Discovery Algorithm (Pomoda) (Zhang et al, in preparation) is a 
position-weight-matrix-optimization method for de novo motif finding from ChIP-seq 
peaks. Pomoda takes into consideration the peak locations and intensities to give more 
weights to the motifs near the center of the peaks and from the peaks with high peak 
intensities. It utilizes all the peaks for motif finding, which is possible to identify all the 














CHAPTER 3: THE CARTOGRAPHY OF ESTROGEN RECEPTOR α, FOXA1 
AND GATA3 BINDINGS IN BREAST CANCER CELLS 
 
3.1 The genome-wide mapping of transcription factor binding events 
We mapped the genome-wide in vivo binding sites of ERα, FOXA1 and GATA3 using 
the massively parallel ChIP-seq in MCF-7 cells before and after estrogen (E2) exposure. 
Using the peak calling algorithm MACS (Zhang et al, 2008), we found a total of 1,990 
high confidence ERα binding sites, 9,337 FOXA1 binding sites and 20,707 GATA3 
binding sites in the vehicle-treated cells (i.e., without ligand) (Figure 21A). 
Upon E2 stimulation, we found a total of 19,412 high confidence ERα binding sites 
(Figure 21B; an increase of ~16.58 fold after normalization of library size, see details in 
Materials and Methods section 2.27 and Table 6), 15,852 FOXA1 binding sites (an 
increase of ~2.46 fold after normalization) and 38,530 GATA3 binding sites (an increase 






Figure 21. The portrait of ERα, FOXA1 and GATA3 binding using the massive parallel 
ChIP-seq approach in the human mammary carcinoma, MCF-7 cells in (A) vehicle-









In order to validate the binding events, several primer pairs were designed around the 
randomly-selected binding sites with different binding intensity and a few non-binding 
sites were also included as the negative control. The ChIP-qPCR results showed 100% 
concordance in calling bound sites (Figure 22 and 23).  
Quantitatively, we found that the ChIP enrichment assayed by ChIP-qPCR for FOXA1 
and GATA3 binding sites were correlated well with the binding intensity measured by 










Figure 22. The validation of FOXA1 binding on randomly selected sites with different 
binding intensity by ChIP-qPCR. A few non-binding sites are included as negative 
control. The error bars show the standard errors of the means of binding enrichments 

























































































































































































































































































Figure 23. The validation of GATA3 binding on randomly selected sites with different 
binding intensity by ChIP-qPCR. A few non-binding sites are included as negative 
control. The error bars show the standard errors of the means of binding enrichments 































































































































































































































































































































































































































Figure 24. The scatter plots on the correlation between (A-B) FOXA1 and (C-D) 
GATA3 peak intensity measured by ChIP-seq after normalization to input control and 






To assess how these TFs individually interact, we overlapped their binding profiles and 
found 37% of ~19k ERα binding sites showed FOXA1 co-localization, while 45% of 
ERα binding sites overlapped with GATA3 binding sites, and as much as 30% of ERα 
binding sites were co-occupied by both FOXA1 and GATA3 (Figure 21). Interestingly, 
the number of sites with occupancy of all three TFs increased from 342 (before estradiol 
exposure) to 5,876 (after estradiol exposure).  
Our data revealed that FOXA1 and GATA3 bindings are symmetrically distributed 
within 200bp around the 5,876 ERα, FOXA1 and GATA3 conjoint binding sites (Figure 
25). The relative intensity of bindings as measured by TF occupancy at these conjoint 
sites was highly correlated amongst the three TFs (R = 0.48-0.63, Figure 26). These 
results suggest that ERα, FOXA1, and GATA3 bind in a coordinated fashion at ~30% of 







Figure 25. The distance distribution of FOXA1 and GATA3 bindings around ERα sites 











Figure 26. The correlation of ERα peaks intensity with (A) FOXA1 and (B) GATA3 
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Figure 27. The illustration of the distribution of binding sites to various genomic 
locations.  Majority of the binding events was found in the enhancer and gene body 
regions (TSS = transcription start site; TES = transcription end site). 







The genomic distribution of binding sites  
inter-genics (20Kb upstream of any TSS, and 2.5Kb downstream of any TSS) 
distal promoters (2.5Kb-20Kb upstream of TSS) 
promoters (+/- 2.5Kb to TSS) 
exons (excluding the regions 2.5Kb from TSS) 
introns (excluding the regions 2.5Kb from TSS) 
3-primes (0-2.5Kb from transcription termination site) 
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We investigated the distribution of the binding sites to various genomic locations and 
found that majority of the binding events occurred at the enhancer regions (Figure 27). 
This observation is in agreement with previously reported works where ERα and FOXA1 
were recruited mainly to the enhancers (Carroll et al, 2006b; Lupien et al, 2008). 
 
3.2 Motif analyses of the TFs binding  
In order to determine the in vivo sequences enriched in the ERα, FOXA1 and GATA3 
occupied sites, we used an in-house program CentDist (Zhang et al, 2011) for known 
motif scanning. This program not only allows for the identification of specific binding 
motifs, but also displays the position-distribution around the binding sites to indicate 
binding specificity. The motif position weight matrixes (PWM) from TRANSFAC 
(Matys et al, 2003) version 11.3 were used and the cutoff of PWM score was set to 1E-3. 
As expected, we found significant enrichment of individual ERE, FOXA1 and GATA3 
motifs in the ERα, FOXA1 and GATA3 ChIP-seq libraries respectively (Figure 28). We 
also observed that the three ERE, FOXA1 and GATA3 binding motifs emerged together 
as the top enriched motifs in each set of the individual TF binding sites, suggesting a bias 
for recognition motifs for all three factors to be clustered together. Besides FOXA1 and 
GATA3 motifs, AP1 and BACH motifs were also enriched in  the ERα binding sites, 
which is in agreement with the previous finding reported by Bhat-Nakshatri et al. (Bhat-
Nakshatri P. et al, 2008).  Because of prior genetic data suggesting a role for FOXA1 and 






Figure 28. Motif scanning around ERα, FOXA1 and GATA3 peaks using CentDist 
(Zhang Z. et al, 2011) .  
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Next, we investigated the de novo motifs enriched in the respective individual ChIP-seq 
libraries. The results revealed that those de novo motifs emerging from the ERα, FOXA1 
and GATA3 binding sites resembled the conventional ERE, FOXA1 and GATA3 motifs 
(Figure 29) with minimal changes comparing the binding sites prior or after E2 
stimulation.  
We specifically assessed the frequency of ERE, FOXA1 and GATA3 binding motifs 
around ERα binding sites. Figure 30 showed that 72% of the ERα sites have an ERE 
motif, 71% of ERα sites contain a FOXA1 motif, 43% of ERα sites contain a GATA3 











Figure 29. The de novo motifs enriched in ERα, FOXA1 and GATA3 binding sites prior 

























3.3 Co-occupancy of ERα+FOXA1 and ERα+GATA3 
Since a large portion of ERα binding sites was bound by FOXA1 and GATA3, we sought 
to dissect the interaction between these three TFs by investigating whether these factors 
are physically co-localized. Using sequential ChIP followed by qPCR in randomly 
selected sites conjointly occupied by ERα+FOXA1 and ERα+GATA3, we found co-
occupancy of these TFs at the overlap binding sites (Figure 31).  
These results suggest that the co-localization of the FOXA1 and GATA3 at ERα 
occupied sites occur through sequence recognition and not solely through a tethering 
mechanism involving only protein-protein interaction. Indeed, extensive co-
immunoprecipitation assays failed to demonstrate direct interaction between ERα and 
FOXA1; ERα and GATA3 in various conditions and cell lines (Eeckhoute et al, 2007; 













Figure 31. The co-occupancy of ERα+FOXA1 (A) and ERα+GATA3 (B) to the target 
cis-regulatory regions as validated by sequential Re-ChIP assay. Genes nearby are used 
to label the peaks, and the tag densities around gene GPR37L1 with ERα+FOXA1 peaks 
and gene PRKCBP1 with ERα+GATA3 peaks are shown as examples. A site near 
LRRN6A gene with only unique ERα binding is recruited as a negative control for the 
sequential Re-ChIP assay. The ChIP enrichment was computed by comparing to the IgG 
pull-down control. Means of at least two independent experiments are compared and 
standard errors are shown. 
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3.4 Progressive recruitment of ERα and FOXA1 to the cis-regulatory elements 
Given the diversity of coregulatory complexes and their mutually exclusive mode of 
interaction with the TFs, it is essential to establish whether the series of TF regulation 
occur randomly or in a sequential fashion. The elegant study by Gannon and colleagues 
(Metivier R et al, 2003) presented an ordered pattern of recruitment and release of 
cohorts of regulatory complexes by examining the ERα-mediated transcriptional 
regulation to the pS2 promoter in breast cancer cells. Hence, it is fascinating to depict the 
enthralling picture of the ordered recruitment of TFs to the regulated units. 
It was previously described that FOXA1 is a pioneering factor characterized by this 
sequence of events: FOXA1 binds to the condensed chromatin in the absence of E2 and 
opens the chromatin to facilitate the ERα binding upon E2 stimulation (Carroll et al, 2005; 
Hurtado A et al, 2011). In addition, it was reported that FOXA1 bound at ERα sites prior 
to ligand stimulation followed by diminished FOXA1 occupancy after E2 exposure 
potentially through displacement by the activated ERα (Carroll et al, 2005). However, we 
observed both an increase in the number of FOXA1 binding sites (9337 to 15852; Figure 
21) and in the average level of occupancy at each site after ligand stimulation (on average 
there were 2.58 reads per peak per million reads in the FOXA1 ChIP-seq library after E2 
stimulation, compared to 1.74 reads per peak per million reads before E2 stimulation).  
We found that 37% (7196/19412) of the ERα binding sites after E2 stimulation were co-
occupied by FOXA1 where 25% (508/1990) of the ERα binding sites were co-occupied 
by FOXA1 in the absence of ligand (Figure 32). This is in accordance to the earlier 
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observations that FOXA1 is preferentially associated with E2-bound ERα (Zhao et al, 
2001). 
If FOXA1 were a true pioneering factor, FOXA1 occupancy would be present in a 
significant percentage of ERα bound sites prior to estradiol exposure. However, our data 
revealed that only 11% (2218/19412; Figure 31) of E2-induced ERα sites are occupied by 
FOXA1 prior to ligand exposure. When we eliminate the number of basal ERα-bound 
sites before E2 stimulation, the percentage of FOXA1 sites that can recruit ERα is 19% 
(=(130+1598)/9337). This means that FOXA1 is a potential pioneering factor to recruit 
only a subset of ERα binding sites. 
Interestingly, view from a different prospective, after excluding the number of basal 
FOXA1-bound sites before E2 stimulation, the percentage of ERα sites that can recruit 
FOXA1 after E2 exposure is 29% (=(573+9)/1990; Figure 31). Thus, ERα can also 
“pioneer” a site for FOXA1 as efficiently as the converse even though, because of a much 
larger starting denominator (9337 sites vs. 1990), it appears that FOXA1 is a better 





Figure 32. The progressive recruitment of ERα and FOXA1 to the cis-regulatory 
elements. Venn diagram of ERα binding sites with vehicle, ERα binding sites after E2 
treatment, FOXA1 binding sites with vehicle, and FOXA1 binding sites after E2 
treatment. We found a total of 1728 (130+1598) ligand-stimulated ERα binding sites that 
could be potentially pioneered by FOXA1. Conversely, a total of 582 (573+9) FOXA1 
binding sites found in E2-treated condition could be recruited by ERα. This suggests that 









To confirm this ChIP-seq based observation, we synchronized the cells with α-amanitin 
treatment followed by E2 stimulation and performed ChIP-qPCR over time on the nucleus 
lysates. The DNA content of the synchronized cells was assessed by cell cycle analysis 
(Figure 33). In the sites where FOXA1 functions as the recruiting factor, we observed 
enrichment of FOXA1 occupancy as early as 5 minutes upon E2 stimulation, followed by 
progressively increasing ERα occupancy at the later time points (e.g., after 10-15minutes, 
example in Figure 34A). Conversely, in those sites where ERα functions as the recruiting 
factor, we show high ERα occupancy at early time points followed by increasing FOXA1 
occupancy at the later time points (example in Figure 34B). Thus, we show that ERα and 






Figure 33. The synchronized MCF-7 cells (A) treated with α-amanitin for 2 hours before 
subjecting to 10nM E2 treatment. The synchronized cells were analyzed with FACS 
(Beckton) revealing that these cells were synchronized to a single G1 phase as compared 
to non-synchronized control cells without α-amanitin treatment (B). The nucleus lysates 












Figure 34. (A)The recruitment of ERα after FOXA1 binding in the synchronized MCF-7 
cells upon E2 stimulation as validated by ChIP-qPCR in various time points. Means of 
two independent experiments with consistent reproducible results are compared and 
standard errors are shown. (B) The recruitment of FOXA1 after ERα binding in the 
synchronized MCF-7 cells upon E2 stimulation as validated by ChIP-qPCR in various 
time points. Means of two independent experiments with consistent reproducible results 







3.5 The formation of enhanceosome consisting of ERα, FOXA1 and GATA3 in 
breast cancer cells 
We have observed the co-localization of ERα, FOXA1 and GATA3 at genomic sites after 
ligand stimulation. We then wished to assess the dynamics of this recruitment by the 
three TFs in response to E2 stimulation. First, we grouped the different subsets of binding 
sites before E2 treatment as ERα unique, FOXA1 unique, GATA3 unique, ERα+FOXA1 
overlap, ERα+GATA3 overlap, FOXA1+GATA3 overlap and ERα+FOXA1+GATA3 
overlap sites as shown in the Venn diagram of Figure 21. We investigated how these 
different subsets of TF bindings clustered after E2 stimulation. We found (Figure 35) a 
dramatic shift of single and double TF binding sites to sites occupied by the three TFs: 
more than 89% of vehicle-treated ERα+FOXA1 overlap sites, 86% of ERα+GATA3 
overlap sites, 30% of ERα unique site, and 28% of the FOXA1+GATA3 overlap sites 
were shifted to the ERα+FOXA1+GATA3 overlap sites in response to E2 induction. By 
contrast, the FOXA1 unique and GATA3 unique sites (before ligand) showed little to no 
shift to the conjoint three factor occupancy state after E2 treatment. This suggests that 
estradiol activation induces the recruitment of FOXA1 and GATA3 with ERα at ERα 





Figure 35. The dynamics of TFs binding before and after E2 stimulation. The different 
categories of ERα, FOXA1 and GATA3 binding sites before E2 stimulation will converge 
to ERα+FOXA1+GATA3 overlapped binding sites after E2 stimulation. 
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It has been previously shown that the functional utility of an ERα binding site is higher 
when these sites are marked by specific and quantitative chromatin signatures: 
functionally active sites have higher ERα occupancy, more open chromatin, and more 
likely to show p300 and RNA polymerase II (RNA Pol II) occupancy. Figure 36-37 
shows that the normalized tag profiles of ERα, FOXA1 and GATA3 at the binding sites 
are strongly enriched after E2 treatment for all the above marks with the 
ERα+FOXA1+GATA3 overlapping conjoint sites having the highest tag occupancy 
profile above all other co-localized categories. In addition, the triple TF overlap sites 










Figure 36. The tabulation of ERα unique, ERα+GATA3, ERα+FOXA1, 
ERα+FOXA1+GATA3 sites with the (A) ERα occupancy (B) FOXA1 occupancy, (C) 






In most instances, compacted chromatin is permissive to direct binding by TFs. One of 
the strategies adopted by TFs to overcome chromatin barrier is to recruit proteins such as 
p300 that can directly remodel chromatin structures in vivo. The p300 coactivator 
possesses intrinsic histone acetyltransferase (HATs) activity capable of modifying the 
chromatin organization, leading to chromatin decondensation and facilitate 
transcriptional initiation (Heintzman et al, 2007). The p300 enrichment is also commonly 
found at the enhancer regions. We observed ERα+FOXA1+GATA3 overlap sites have 
the highest p300 coactivator occupancy (Figure 37A).  
In addition to ERα binding and targeted chromatin modification, the initiation of 
transcription at estrogen-responsive promoters also requires the recruitment of RNA Pol 
II. Previously, we have determined that RNA Pol II co-binding at ERα binding sites is 
related to distant interactions linking the enhancer sites with the transcription start sites 
(Fullwood et al, 2009). In Figure 37B, we show that ERα+FOXA1+GATA3 overlap sites 
have the highest RNA Pol II occupancy with ERα+FOXA1 double overlap sites 
following closely.  
Chromatin is a well-known obstacle to transcription as it controls DNA accessibility, 
which directly impacts on the activation of transcriptional machinery. The degree of 
chromatin compaction is intimately related to its functionality and these can be identified 
using formaldehyde-assisted isolation of regulatory elements (FAIRE) that allows for 
enrichment of nucleosome-depleted genomic regions when cross-linked chromatin is 
subjected to phenol-chloroform extraction (Boyle AP. et al, 2008). Understanding how 
the chromatin landscape is shaped is essential to decipher the spatial and temporal fine-
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tuning of ER transcriptional programs. When we assessed the chromatin state with 
FAIRE (Joseph et al, 2010), we found that ERα+FOXA1+GATA3 and ERα+FOXA1 
overlap sites have the highest association with chromatin opening (Figure 37C). This 
suggests that these triple overlap sites (ERα+FOXA1+GATA3) are potentially the most 
active enhancers affecting ERα transcriptional regulation and that there appears to be a 
hierarchy of associative effect: FOXA1 contributing the most to ERα enhancer function 
and GATA3 being less impactful (Figure 37C).  
Next, we investigated the distribution of the triple overlap/ enhanceosome sites in the 
ERα binding dataset. Interestingly, we found that majority of the enhanceosome sites 
(57%) present in the 1
st
 quartile of ERα binding sites with highest ERα binding intensity, 
while only 7% of the enhanceosome sites reside in the 4
th
 quartile of ERα binding sites 










Figure 37. (A)The enhanced p300 coactivator recruitment to enhanceosome sites after E2 
stimulation. (B) The highest association of RNA Pol II recruitment with enhanceosome 
sites after E2 stimulation. (C) The enhanceosome is correlated with chromatin opening as 







Figure 38. The distribution of enhanceosome consists of ERα+FOXA1+GATA3 in the 
~19k ERα binding sites in MCF-7 cells. Majority of the enhanceosomes were found in 












Distribution of ER+GATA3+FOXA1 overlap sites in 







This observation raises the question whether the enhanceosome impact is solely driven by 
the strong ERα binding instead of the cooperative regulation by ERα+FOXA1+GATA3 
TFs.  In order to interrogate this, we separated the 1
st
 quartile of ERα binding sites of 
highest binding intensity into two categories based on the presence or absence of triple 
overlap/ enhanceosome sites. We found the enhanceosome impact is independent of ERα 
occupancy intensity since the triple overlap/enhanceosome sites (ERα+FOXA1+GATA3) 
bear the marks for optimal enhancer with the highest individual TF, p300 and RNA Pol II 
occupancy while the non-enhanceosome sites have less association with the enhancer 
marks though all these sites were from the top quartile of ERα sites of highest binding 
intensity (Figure 39). Hence, we concluded that the enhanceosome impact is indeed 
driven by the cooperative regulation by ERα, FOXA1 and GATA3.  
Next, we asked the question whether the enhanceosome found in MCF-7 cells can be 
generalized in other breast cancer cells. In our recent work (Joseph et al, 2010), we have 
provided the evidence that the common ERα sites found in both MCF-7 cells and another 
breast cancer cell line, T47D cells represented the sites with the highest association with 
ERE score, H3K4me1, FOXA1 occupancy and chromatin opening. Interestingly, we 
observed that as much as 52% of the common ERα sites found in MCF-7 and T47D cells 
exhibit enriched FOXA1 and GATA3 binding (Figure 40A-B). Furthermore, the common 
ERα sites overlapped with FOXA1 and GATA3 bindings displayed higher ERα binding 
intensity as compared to non-overlapped common ERα sites (Figure 40C).  
Recent publication by Carroll and co-workers has revealed a list of core ERα binding 
events that is present in the ERα-positive breast tumors and absent in the ERα-negative 
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tumors (Ross-Innes C.S. et al, 2012). In order to address whether the genomic impact by 
enhanceosome in MCF-7 cells would be relevant in primary tumors, we overlapped our 
enhanceosome binding sites with the core ERα binding sites found in ERα-positive breast 
tumors. Remarkably, we found that more than 82% of these core ERα binding events in 
breast tumor overlapped with our enhanceosome sites (Figure 41). This suggests that the 
impact of enhanceosome beyond MCF-7 cell model. Moreover, when we overlapped our 
enhanceosome sites with the ERα binding events that were differentially enriched in 
tumors with good or poor prognosis/ distant metastasis, we found that there is better 
overlap between the MCF-7 enhanceosome sites with the poor prognosis ER binding 
events. This could be explained by the fact that MCF-7 cell line was derived from 
metastatic mammary tumor and hence it is more similar to tumor with poor prognosis/ 










Figure 39. The comparison  between enhanceosome (red) vs non-enhanceosome (green) 
from the top quartile ERα sites for the occupancy of ERα, FOXA1 and GATA3 (A-C); 








Figure 40. The enhanceosome found in MCF-7 cells can be generalized in another breast 
cancer cell line, T47D. (A) There was 52% of the common ERα sites shared between 
MCF-7 and T47D cells. (B) More than half of the common ERα sites exhibited enriched 
FOXA1 and GATA3 bindings. (C) The common ERα sites overlapped with FOXA1 and 
GATA3 bindings displayed higher ERα binding intensity as compared to non-overlapped 









Figure 41. (A) The overlap between MCF-7 enhanceosome sites with core ER binding 
sites in ERα-positive breast tumors. (B) The overlap between MCF-7 enhanceosome sites 
with ER binding events enriched in tumors with good prognosis. (C) There is more 
overlap between MCF-7 enhanceosome sites with ER binding events enriched in tumors 






3.6 The enhanceosome is associated with three-dimensional ERα-regulated long-
range interactome 
The chromatin landscape is defined as the combination of parameters that influence its 
function that include the higher-order folding and related three-dimensional organization. 
It is known that TFs can interact through long-range chromatin interactions to regulate 
the transcriptional networks. Recently, a new method known as Chromatin Interaction 
Analysis with Paired-End-Tag sequencing (ChIA-PET) has been developed (Fullwood et 
al, 2009; Li et al, 2010) to characterize the long-range chromatin looping mediated by 
ERα in MCF-7 cell line. After re-analyzing the ERα ChIA-PET data, we observed that 81% 
of the 5067 interaction clusters have at least one anchor region (an ERα binding site 
associated with a distant chromatin interaction forming at least one loop) characterized by 
ERα+FOXA1+GATA3 co-localization. Furthermore, the interaction clusters from ChIA-
PET can form complex clusters that organize the local genomic region into multiple 
loops. These complex interaction clusters also demarcate the most significantly ERα 
regulated genes (Fullwood et al, 2009). Of the 5067 ERα mediated long-range interaction 
clusters, 4500 clusters are involved in complex interaction clusters, and 567 clusters are 
involved in duplex interaction clusters (Figure 42). 88% of the complex interaction 
clusters are associated with ERα+FOXA1+GATA3 overlapped binding sites, while 51% 
of the duplex interaction clusters have the support of ERα+FOXA1+GATA3 overlapped 






Figure 42. The illustration of an example of (A) duplex and (B) complex interaction is 









Figure 43. Majority of the ERα interactomes display ERα+FOXA1+GATA3 co-
localization. (A) The distribution of simple/ duplex ChIA-PET interaction clusters with 
ERα+FOXA1+GATA3 conjoint bindings. (B) The complex ChIA-PET interaction 
clusters with ERα+FOXA1+GATA3 conjoint bindings. We found that the enhanceosome 
has better association with complex ERα interactome, indicating that interactome of 





Since complex interaction clusters mark genes most responsive to E2 as compared to 
duplex clusters, these data support the notion that the presence of the ERα, FOXA1, and 
GATA3 putative enhanceosome is associated with genes that are most responsive to E2.  
A specific example of the ERα mediated long-range interactions involving conjoint ERα, 
FOXA1 and GATA3 binding sites around the highly E2 responsive GREB1 gene is 
shown in Figure 44. These triple TF conjoint binding sites are highly represented at the 







Figure 44. An example of E2-regulated gene with complex ERα interactome was shown 








3.7 The impact of ERα+FOXA1+GATA3 enhanceosome in regulating E2-responsive 
genes 
We have provided evidence that the clustering of ERα, FOXA1 and GATA3 at ERα 
binding sites is associated with chromatin characteristics of the most active ERα 
enhancers. To assess the effect of this enhanceosome presence on direct gene regulation, 
we performed a detailed microarray expression analysis to determine E2-responsive genes 
in MCF-7 cells.  We found a total of 653 up-regulated and 1249 down-regulated genes in 
response to E2 stimulation. We assigned a specific known gene to a binding site occupied 
by any combination of the three TFs if the peak of each TF category is the nearest and 
within 20kb of TSS of that E2 responsive gene. Figure 45A shows that, for the genes with 
ERα, FOXA1 and GATA3 peaks or any combination, the biggest proportion of either up- 
or down-regulated genes are from genes with adjacent ERα+FOXA1+GATA3 conjoint 
binding sites within 20kb of their TSS (28% and 30% respectively).  Since the different 
binding sites are present in the genome at different frequencies, the ratio of regulated vs. 
non-regulated genes for each binding site class can be used to normalize the differences. 
The proportion of up-regulated genes with ERα, FOXA1 and GATA3 conjoint peaks is 
2.3 fold of the non-regulated genes with the same configuration. This is contrasted by 
genes adjacent to other combinations of ERα, FOXA1 and GATA3 binding which do not 
show significant changes as compared to non-regulated genes. The only exception is the 
proportion of genes close to FOXA1+GATA3 co-bound sites which are associated with 
greater down-regulated genes.  Despite this association, the percentage of down-regulated 
genes putatively controlled jointly by FOXA1 and GATA3 is relatively small.  
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Finally, the presence of the three TFs relative to a regulated gene may have two 
configurations: one where the ERα binding site has conjoint and therefore overlapping 
occupancy by all three TFs, and the other where the binding of the individual TFs are in 
proximity with each other and within 20kb of a gene, but the binding sites are not 
overlapping (Figure 45B).  
When we analyzed the association of E2-regulated genes with these two categories 
(overlapping and non-overlapping), we found that the predominant association is between 
the conjoint binding sites and regulated genes (Figure 45B).   Our results imply that ERα-
regulation of gene expression is closely linked to adjacency with sites that show conjoint 














Figure 45. The classification of ERα+FOXA1+GATA3 conjoint binding sites into two 
configurations: (A) non-overlapped ERα+FOXA1+GATA3 peaks and, (B) overlapped 
ERα+FOXA1+GATA3 peaks within 20kb of the TSS. 
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Using Gene Ontology (GO) analysis (Thomas et al, 2003), we sought to further ascertain 
the importance of genes in proximity with enhanceosome binding as compared to binding 
of the individual TF components. We found that only genes associated with 
ERα+FOXA1+GATA3 binding have significant association (with P values up to 6.7E-26) 
with specific biology processes known to be involved in ERα signaling (eg. signal 
transduction, cell proliferation), molecular function (eg. kinase, protein binding) and 
signaling pathways (eg. PDGF signaling pathway, inflammation mediated by chemokine 
and cytokine signaling pathway) (Tables 7-9). Thus, the identification of the ERα 
enhanceosome associated genes allows for the identification of a “core” set of ERα 
regulated genes that are strongly associated with the cognate cellular functions previously 
known for ERα. This result implies that the cooperativity of the enhanceosome 
components not only facilitate binding of the activators to DNA but also position them to 

























cellular process 6.71E-26 1.14E-05 N. S. 1.61E-07 
cell communication 1.48E-19 8.06E-08 N. S. 9.69E-05 
developmental 
process 
2.08E-19 N. S. N. S. N. S. 
signal transduction 1.58E-17 6.34E-08 N. S. N. S. 
system development 7.60E-13 N. S. N. S. N. S. 
intracellular 
signaling cascade 
1.75E-12 N. S. N. S. N. S. 
system process 3.44E-12 N. S. N. S. N. S. 
cell motion 3.61E-12 N. S. N. S. N. S. 
ectoderm 
development 
1.02E-11 N. S. N. S. N. S. 
cellular component 
morphogenesis 
3.96E-11 N. S. N. S. N. S. 
anatomical structure 
morphogenesis 
3.96E-11 N. S. N. S. N. S. 
transport 3.96E-11 N. S. N. S. N. S. 
neurological system 
process 
4.17E-11 N. S. N. S. N. S. 
nervous system 
development 
1.69E-10 5.95E-05 N. S. N. S. 
cellular component 
organization 
1.20E-09 N. S. N. S. N. S. 
cell adhesion 2.31E-09 N. S. N. S. N. S. 
mesoderm 
development 
4.05E-09 N. S. N. S. N. S. 
sensory perception 1.06E-08 N. S. N. S. N. S. 
Note: N.S.  means “not significant with p-value larger than 1E-04” 
 
Table 7. Gene ontology analysis of genes associated with different categories of ERα, 
FOXA1, GATA3 bindings. The genes associated with ERα+FOXA1+GATA3 
overlapped binding sites have significant functions, compared to genes only with 























PDGF signaling 1.41E-07 N.S. N.S. N.S. 
Heterotrimeric G-protein 
signaling 
3.92E-05 N.S. N.S. N.S. 
Inflammation mediated 
by chemokine and 
cytokine signaling 
2.81E-05 N.S. N.S. N.S. 
Histamine H1 receptor 
mediated signaling 
1.86E-05 N.S. N.S. N.S. 
Note: N.S.  means “not significant with p-value larger than 1E-04” 
Table 8. The Gene Ontology analysis (Pathway) for genes with ERα+FOXA1+GATA3 




































Protein binding 1.59E-15 3.90E-07 N.S 7.29E-06 
Small GTPase 
regular activity 




2.51E-12 N.S N.S 1.55E-05 
Catalytic 
activity 





9.82E-09 N.S N.S N.S 
Binding 1.09E-08 N.S N.S 1.76E-06 
Transporter 
activity 




1.23E-07 N.S N.S N.S 
Transferase 
activity 
7.96E-07 N.S N.S 3.37E-07 




8.41E-06 N.S N.S N.S 
Calcium ion 
binding 
1.71E-05 N.S N.S N.S 
Note: N.S.  means “not significant with p-value larger than 1E-04” 
Table 9. The Gene Ontology analysis (Molecular Function) for genes with 
ERα+FOXA1+GATA3 bindings as compared to genes with ERα unique, FOXA1 unique 






To further validate that ERα+FOXA1+GATA3 co-binding represents an optimal 
configuration for E2-mediated transcriptional activation, we have performed luciferase 
reporter assays on GREB1 locus that actively engages ERα enhanceosome sites in gene 
regulation (Figure 46A). We cloned the promoter region of GREB1 that includes a 
ER+FOXA1+GATA3 enhanceosome binding site into the pGL4-luciferase reporter 
construct and then transfected GREB1-luciferase promoter construct into ER negative 
MDA-MB-231 cells, followed by transfection and over-expression of ERα, FOXA1 
and/or GATA3. The individual presence of FOXA1 and GATA3 or combination of both 
only produced subtle changes to the GREB1 luciferase activity, demonstrating that the 
presence of FOXA1 and GATA3  alone or combination of both do not activate the 
transcription of GREB1 gene (Figure 46B). The presence of ERα induced the GREB1 
luciferase activity to ~246% (as compare to the control construct). The combination of 
ERα+FOXA1 and ERα+GATA3 has increased the luciferase activity to ~330% (an 
increment of 26-32%). Interestingly, the assemblage of ERα+FOXA1+GATA3 provided 
the optimal ER responsiveness to 370% representing an additional 12-14% increment. 
This suggests that ERα provides the fundamental gene regulatory module but that 






Figure 46. (A) The GREB1 locus that is engaged with enhanceosome recruitment. 
(B)The presence of ERα, FOXA1 and GATA3 has induced the luciferase activity of 
GREB1 gene in MDA-MB-231 cells. The basal luciferase activity of GREB1 in MDA-
MB-231 cells is used as the control reference. Means of three independent experiments 





Such artificial transfection reporter systems accentuate TF responses because of unnatural 
stoichiometries of the TFs. To further assess the interplay among ERα, FOXA1 and 
GATA3, we perturbed the binding of these TFs in MCF-7 cells through the site-directed 
mutagenesis assay and asked whether the loss of individual binding motifs would alter 
gene regulation under physiologic concentrations of the three TFs. Different GREB1-
luciferase constructs with mutated ERE, FOXA1 or GATA3 motif at the specific ERα, 
FOXA1 and GATA3 binding sites were generated. The results revealed that individually 
mutated FOXA1 or GATA3 motif only imposed 25-30% loss of GREB1 luciferase 
activity (Figure 47). Mutated ERE alone has repressed the luciferase measurement to 
~50%. Interestingly, combinatorial ERE+FOXA1 and ERE+GATA3 mutation further 
reduced the luciferase activity by ~65-70% suggesting that the effects of the individual 
TFs on this putative enhanceosome are additive. Here, we can build a hierarchy of TFs 
control, showing that ERα accounts for 50% of the transcriptional control while FOXA1 
and GATA3 individually account for another 20% transcriptional control at the GREB1 
gene regulatory locus. 
Next, we asked if the enhanceosome impacts on gene regulation is merely driven by 
induced expression of ERα, FOXA1 and GATA3 upon E2 stimulation. We performed 
western blot on MCF-7 lysates prior and after estrogenic stimulation, the data revealed 
unaltered expression of these TFs upon E2 treatment (Figure 48). This suggests that the 
enhanceosome impacts that we observed is not caused by the mass action of induced TFs 
expression, instead it is motivated by the activated and enhanced recruitment of TFs to 








Figure 47. The loss of FOXA1 and/or GATA3 bindings has reduced the luciferase 
activity of GREB1 gene in MCF-7 cells. “mER”, “mFOXA1” and “mGATA3” denote 
mutated ERE, FOXA1 and GATA3 motif sequences around their respective binding sites 
near the GREB1 promoter. The basal luciferase activity of GREB1 in MCF-7 wild-type 
cells is served as the control reference. Means of three independent experiments are 









Figure 48. There were unaltered ERα, FOXA1 and GATA3 expression levels prior and 














CHAPTER 4: FOXA1 AND GATA3 ARE ESSENTIAL COREGULATORS IN 
MEDIATING THE ERα-GROWTH RESPONSE  
4.1 The co-expression of ERα, FOXA1 and GATA3 is required for estrogen-
responsive growth 
It is known that ERα is a ligand-activated TF that mediates the proliferative effects of E2 
in breast cancer cells. Garcia et al. (Garcia et al, 1992) showed inhibited growth in MDA-
MB-231 cells with forced expression of ERα upon E2 treatment. The rationale for these 
different outcomes has remained elusive. We hypothesize that the absence of critical 
coregulators such as FOXA1 and GATA3 are responsible for the ERα response cassette.  
To test this hypothesis, we stably transfected the MDA-MB-231 cells with individual 
ERα, FOXA1, GATA3 or in combination. The induction of ERα, FOXA1 and GATA3 
expressions following transfections were verified (Figure 49).  
We assessed the cell proliferation in response to E2 stimulation using two assays: WST-1 
and cell count using Hoechst stain. In parallel to the reports by Garcia et al. (Garcia et al, 
1992) and Wolf et al. (Wolf et al, 2007), we observed marginally inhibited growth in 
cells with forced expression of ERα and a greater inhibitory effect with forced expression 
of FOXA1. There was unaltered growth in cells with expression of GATA3. 
Coexpression of ERα and FOXA1; ERα and GATA3 exhibited inhibition of cell 
proliferation as compared to control cells. However, the coexpression of ERα together 
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with FOXA1 and GATA3 resulted in marked induction of cell proliferation under E2 
stimulation as assessed by either growth detection assays (Figure 50-51).   
We have recapitulated this cellular reprogramming in another ERα-negative breast cancer 
cell line, BT-549 and observed similar growth inhibition in BT-549 cells expressing ERα 
and FOXA1 individually (Figure 52-53). We found minor induction of growth in 
GATA3-expressing BT-549 cells, however this growth was independent of E2 
stimulation. However, like MDA-MB-231 cells, we were able to induce E2-dependent 
growth in ERα+FOXA1+GATA3-expressing BT-549 cells (Figure 54). 
This suggests that only with the full activation of conjoint binding sites by the three TFs 
will the proliferative phenotype associated with ligand induced ER be manifest. This 
further suggests that like induced pluripotent stem cells (iPS cells) only the combination 
of multiple factors (in this case, ERα, FOXA1 and GATA3) can transcriptionally 
reprogramme MDA-MB-231 and BT-549 cells to be estrogen responsive for growth. Our 
observation on the induced growth observed at 10 days after estrogen stimulation was 
akin to the iPS reprogramming, where the presence of reprogramming TFs and the time 
in culture has led to the accumulation and selection of novel genomic aberrations which 
were quantitatively of the same magnitude as those inflicted during the iPS 






Figure 49. The expression of ERα, GATA3 and FOXA1 in ERα-positive MCF-7 cells 
and ERα-negative MDA-MB-231 and BT-549 cells prior to transfection experiment. (B) 
The expression of ERα, GATA3 and FOXA1 in the transfected MDA-MB-231 and BT-





Figure 50. The proliferation of reprogrammed MDA-MB-231 cells assayed by WST-1. 
(A) The subtle inhibited growth of MDA-MB-231 cells with the transfection of ERα. (B)  
The inhibited growth of MDA-MB-231 cells with the transfection of FOXA1. (C) The 
unaltered growth of MDA-MB-231 cells with the transfection of GATA3. (D) The 
inhibited growth of MDA-MB-231 cells with co-transfection of ERα+FOXA1. (E) The 
unaltered growth of MDA-MB-231 cells with co-transfection of ERα+GATA3. (F) The 
induced cell proliferation in response to E2 stimulation in the MDA-MB-231 cells with 
the co-transfection of ERα, FOXA1 and GATA3 in combination. For every sub-figure, 










Figure 51. The proliferation of reprogrammed MDA-MB-231 cells assessed by cell 
number count using Hoechst stain. (A) The subtle inhibited growth of MDA-MB-231 
cells with the transfection of ERα. (B)  The inhibited growth of MDA-MB-231 cells with 
the transfection of FOXA1. (C) The unaltered growth of MDA-MB-231 cells with the 
transfection of GATA3. (D) The unaltered growth of MDA-MB-231 cells with co-
transfection of ERα+FOXA1. (E) The inhibited growth of MDA-MB-231 cells with co-
transfection of ERα+GATA3. (F) The induced cell proliferation in response to E2 
stimulation in the MDA-MB-231 cells with the co-transfection of ERα, FOXA1 and 
GATA3 in combination. For every sub-figure, means and standard errors of three 









Figure 52. Recapitulating the reprogramming work in another ERα-negative BT-549 cell 
line assayed by WST-1. (A) The inhibited growth of BT-549 cells with the transfection of 
ERα. (B)  The inhibited growth of BT-549 cells with the transfection of FOXA1. (C) The 
subtle induced growth of BT-549 cells with the transfection of GATA3. (D) The 
unaltered growth of BT-549 cells with co-transfection of ERα+FOXA1. (E) The 
unaltered growth of BT-549 cells with co-transfection of ERα+GATA3. (F) The induced 
cell proliferation in response to E2 stimulation in the BT-549 cells with the co-
transfection of ERα, FOXA1 and GATA3 in combination. For every sub-figure, means 




























Figure 53. The proliferation of reprogrammed BT-549 cells assessed by cell number 
count using Hoechst stain. (A) The subtle inhibited growth of BT-549 cells with the 
transfection of ERα. (B)  The inhibited growth of BT-549 cells with the transfection of 
FOXA1. (C) The marginal induced growth of BT-549 cells with the transfection of 
GATA3. (D) The inhibited growth of BT-549 cells with co-transfection of ERα+FOXA1. 
(E) The inhibited growth of BT-549 cells with co-transfection of ERα+GATA3. (F) The 
induced cell proliferation in response to E2 stimulation in the BT-549 cells with the co-
transfection of ERα, FOXA1 and GATA3 in combination. For every sub-figure, means 





Figure 54. FOXA1 and GATA3 are essential components of E2-induced ERα-response 
casette.  (A) The growth of MDA-MB-231 cells transfected with different combinations 
of TFs relative to the vehicle-treated MDA-MB-231 vector control cells at the final day 
of WST-1 measurement.  (B) The recapitulation of reprogramming work in another ERα-
negative BT-549 cells. The growth of BT-549 cells tranfected with different 
combinations of TFs relative to the vehicle-treated BT-549 vector control cells at the 




4.2 The co-existence of ERα, FOXA1 and GATA3 in modulating the luminal and 
basal cassettes of the reprogrammed cells 
Next, we asked if the reprogrammed MDA-MB-231 and BT-549 cells have acquired 
luminal cell characteristics. We investigated the expression of luminal and basal markers 
genes defined by Kao et al. (Kao J et al, 2009) in the transfected MDA-MB-231 and BT-
549 cells.  The analysis revealed a modest but discernible induction of luminal markers 
genes and suppression of basal marker genes in the ERα+FOXA1+GATA3-expressing 
MDA-MB-231 and BT-549 cells as compared to the ERα-only or vector control cells 
(Figure 55-56). Therefore, the enhanceosome consists of ERα, FOXA1 and GATA3 not 
only ‘step on the accelerator’ to induce a new gene expression program, but also ‘put on 
the brakes’ to inactivate the regulators of existing cell type, leading to extinction of 
markers characteristic of the old phenotype.  
Moreover, we found that 63% of the luminal genes are associated with conjoint binding 
of the three transcription factors ERα+FOXA1+ GATA3 within 20 kb of the TSS,   and 
only 13% of these luminal genes showing no proximity binding of  any of these 3 TFs. 
On the other hand, 24% of the basal genes are associated with proximate conjoint 
ERα+FOXA1+ GATA3 binding with 40% of these genes are not associated with any 






Figure 55. We compared the expression profile of luminal and basal marker genes 
defined by Kao J et al. in the transfected MDA-MB-231 cells. (A) We observed that there 
is induced expression of luminal marker genes in the ERα+FOXA1+GATA3-expressing 
MDA-MB-231 cells as compared to ERα-only or vector-control MDA-MB-231 cells. We 
included the expression of MCF-7 cells that is defined as luminal subtype as comparison. 
(B) There is reduced expression of basal marker genes in the ERα+FOXA1+GATA3-
expressing MDA-MB-231 cells as compared to ERα-only or vector-control MDA-MB-
231 cells. (C) This bar plot represented the average expression difference of luminal and 
basal marker genes in ERα+FOXA1+GATA3-expressing MDA-MB-231 cells as 























Expression differences in MDA-MB-231-









Figure 56. We compared the expression profile of luminal and basal marker genes 
defined by Kao J et al. in the transfected BT-549 cells. (A) We observed that there is 
induced expression of luminal marker genes in the ERα+FOXA1+GATA3-expressing 
BT-549 cells as compared to ERα-only or vector-control BT-549 cells. We included the 
expression of MCF-7 cells that is defined as luminal subtype as comparison. (B) There is 
reduced expression of basal marker genes in the ERα+FOXA1+GATA3-expressing BT-
549 cells as compared to ERα-only or vector-control BT-549 cells. (C) This bar plot 
represented the average expression difference of luminal and basal marker genes in 
ERα+FOXA1+GATA3-expressing BT-549 cells as compared to vector-control MDA-
MB-231 cells (* denotes p-value ≤ 0.01 compared to the vector-control cells computed 































Figure 57. The presence of ERα, FOXA1 and GATA3 bindings at 20kb around the TSS 
of  luminal and basal marker genes defined by Kao et al. (A) We demonstrated that ERα, 
FOXA1 and GATA3 bindings present in 63% of the luminal marker genes, only 13% of 
these luminal marker genes have no association with either TF binding. (B) The ERα, 
FOXA1 and GATA3 bindings are only present in 23% of the basal marker genes while 




This suggests that ERα+FOXA1+GATA3 binding exerts greater impact on regulating the 
transcription of luminal marker genes as compared to the basal marker genes. Taken 
together, we demonstrate that the co-expression of the ERα enhanceosome components, 


















CHAPTER 5: THE CORE ESTROGEN-RESPONSIVE CASSETTE THAT 
DRIVES THE GROWTH AND PROLIFERATION OF BREAST CANCER 
CELLS 
5.1 The presence of ERα, FOXA1 and GATA3 has reprogrammed the 
transcriptome of ERα-negative cells to acquire the transcriptome of ERα-positive 
cells 
Though the estrogen-driven growth and proliferation is a well-defined signature for ERα-
positive breast cancer cells, significant gap of knowledge still exists especially in the 
understanding on how this hormone controls the growth and proliferation of neoplastic 
breast epithelium. To address this, we wish to investigate the estrogen-mediated gene 
regulation in the breast cancer and the manner in which these changes in gene expression 
affect breast cancer proliferation. 
In order to assess the nature of the transcriptional reprogramming, we asked the question 
if the reprogrammed MDA-MB-231 and BT-549 cells display any similarity in the 
expression profile of the ERα-positive breast cancer cell line, MCF-7. Gene expression 
profiling was performed on the ERα-only and ERα+FOXA1+GATA3 transfectant cells. 
We compared the E2-regulated genes from these differently transfected MDA-MB-231/ 
BT-549 cells with MCF-7 cells. Strikingly, we found that the expression profile of E2 
induced ERα+FOXA1+GATA3 expressing MDA-MB-231 cells display a good positive 
correlation (R=0.42) with the E2 induced expression profile of MCF-7. By contrast, we 
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observed a negative correlation between the expression profiles of MDA-MB-231 
transfected with ERα only (R= -0.21) (Figure 58). We observed the similar negative 
correlation (R= -0.12) in the ERα-only BT-549 cells and positive correlation (R = 0.16) 
in ERα+FOXA1+GATA3 expressing BT-549 cells with MCF-7 though in a weaker 
correlation strength. Though the temporal expression regulated by the three TFs in MDA-
MB-231 and BT-549 cells does not mimic the temporal expression patterns of the MCF-7 
cells precisely, it resulting in the same outcome, suggesting that these transcriptional 
networks are highly robust. 
 
5.2 The reprogrammed cells regulate the cell cycle and proliferation genes in a 
similar manner with the ERα-positive MCF-7 cells 
Using the Ingenuity Pathway Analysis (IPA), we observed that the estrogen responsive 
genes regulated in MDA-MB-231and BT-549 transfectant cells were significantly 
associated with cell cycle, cellular proliferation and DNA replication functionalities (p-
value = 7.27E-12 – 1.28E-04; 5.59E-07-1.82E-02, Table 10). In addition, when only cell 
cycle and proliferation genes were examined, again, there was positive correlation 
between MDA-MB-231 and BT-549 transfected with ERα+FOXA1+GATA3 and MCF-7 
but no correlation between ERα-only MDA-MB-231 and BT-549 cells with MCF-7 








Figure 58. The comparison of gene profilings in reprogrammed MDA-MB-231 and BT-
549 with MCF-7 cells. (A) The gene profilings of ERα-only MDA-MB-231 cells show 
weak correlation with the expression profiles of MCF-7 cells.(B) The 
ERα+FOXA1+GATA3-expressing MDA-MB-231 cells display good correlation with the 
expression profile of ERα-positive MCF-7 cells. (C) The gene profilings of ERα-only 
BT-549 cells show negative correlation with the expression profiles of MCF-7 cells.(D) 
The ERα+FOXA1+GATA3-expressing BT-549 cells display positive correlation with the 









Figure 59.  The correlation of the expression profile of cell cycle and cellular 
proliferation genes between the MCF-7 cells, and the MDA-MB-231 cells transfected 
with (A) ERα-only, and (B) ERα+FOXA1+GATA3; and BT-549 cells transfected with 
(C) ERα-only, and (D) ERα+FOXA1+GATA3 .  We observed that there was positive 
correlation between MDA-MB-231 and BT-549 cells transfected with 
ERα+FOXA1+GATA3 and MCF-7 cells; and negative correlation between the ER-only 







p-value for MDA-MB-231 
transfectant cells 
p-value for BT-549 
transfectant cells 
Cell Cycle 7.27E-12-4.69E-04 
 
5.59E-07-1.94E-02 
Cellular Growth and Proliferation 1.84E-08-4.74E-04 
 
6.52E-06-1.82E-02 
DNA Replication, Recombination, 




Table 10. The Ingenuity Pathway Analysis (IPA) was used to access the functionality of 
estrogen responsive genes identified in MDA-MB-231 and BT-549 transfectant cells. The 
estrogen regulated genes identified in the transfected MDA-MB-231 and BT-549 sublines 















Moreover, we found that there is up-regulation of pro-proliferative cell cycle genes in the 
ERα+FOXA1+GATA3-expressing MDA-MB-231 and BT-549 cells compared to ERα-
only cells (Figure 60). We assessed specific genes previously known to be E2-regulated in 
ERα responsive cell lines such as CCND1, STC2, ABCA3 and  DUSP3 (Frasor J. et al, 
2003; Lin C. Y. et al, 2004), we found that these genes were also regulated in the same 
direction by ligand in the triple factor transfected MDA-MB-231 or BT-549 cells.  
Next, we performed ChIP-seq in the reprogrammed MDA-MB-231 and BT-549 cells to 
investigate the ERα binding profiles. Intriguingly, we found there are consistently more 
ERα binding events in the ERα+FOXA1+GATA3-expressing cells compared to the ERα-
only cells (Table 11).  Most importantly, we observed that there are more ERα binding 
events at day 10, suggesting that there is progressive recruitment of ERα in the 








Figure 60. The differential regulation of cell cycle and proliferation genes in the (A) 








GATA3, 45 min 
ERα+FOXA1+ 





MDA-MB-231 2666 3777 934 940 
BT-549 2962 4284 2465 1544 
 
Table 11. The ERα binding events in the reprogrammed MDA-MB-231 and BT-549 cells 















We then segregated the ERα binding sites to different categories unique to early (45 
minutes) or late (day 10) binding events in ERα+FOXA1+GATA3 or ERα-only cells 
respectively. We annotated the genes to nearest ERα binding site within ±50kb of TSS, 
we observed that genes annotated to those unique ERα binding sites in 
ERα+FOXA1+GATA3 cells were significantly associated with gene expression, cellular 
assembly and organization, growth and proliferation as well as cell signaling which is 
absent in the ERα-only cells (Figure 61-62). 
Taken together, these results suggest that the presence of ERα, FOXA1 and GATA3 has 
transcriptionally reprogrammed the ERα-negative MDA-MB-231 as well as the BT-549 
cells to resemble the ERα-positive MCF-7 cells by recapitulating the estrogen responsive 
cassette and manifesting the proliferative phenotype. This suggests that modulation of 
signaling pathways is able to induce transdetermination (conversion between two closely 








Figure 61. IPA was performed on genes annotated to unique (A) early and (B) late ERα 
binding events in reprogrammed ERα+FOXA1+GATA3-expressing and ERα-only 







Figure 62. (A) IPA was performed on genes annotated to unique early ERα binding 
events in reprogrammed ERα+FOXA1+GATA3-expressing and ERα-only BT-549 cells. 
(B) Since there is no unique late ERα binding event in the ERα-only cells, only the genes 
associated with late ERα binding events in ERα+FOXA1+GATA3-expressing cell were 





CHAPTER 6: DISCUSSION 
Estrogen receptor, as a prototype of a nuclear hormone receptor, mediates a broad range 
of cellular and physiologic functions with organ and context specificity. The most 
proximate form of regulatory control resides in the protein-DNA interaction of TF 
binding to their cognate recognition motifs and modified by co-factors. However, 
genome-wide studies of ERα binding show a dispersed occupancy pattern at binding sites 
bearing heterogeneous recognition motifs that are, at the sequence level, also not well 
conserved in evolution (Kunarso G et al, 2010). This binding site heterogeneity is 
normalized by chromatin looping to bring these distant and distributed enhancers in 
proximity to the regulated TSS (Fullwood et al, 2009). Herein, we show that FOXA1 and 
GATA3 are essential for optimal ERα binding to DNA, that FOXA1 and GATA3 are 
recruited as a complex to the most functional ERα binding sites after ligand activation, 
and that the binding of this tripartite enhanceosome complex of ERα, FOXA1, and 
GATA3 is necessary for optimal transcriptional activation in reporter gene assays. The 
enhanceosome assembly is recruited to sites bearing the three recognition motifs suggests 
that this complex formation is "hard-wired" in the human genome and provides an 
evolutionary advantage. This notion is supported by the fact that the co-localization of the 
motifs for these TFs was found in 23,090 sites in the reference human genome, but in 
only 360 sites in a random nucleotide sequences for a 64 fold enrichment.  This compares 
to a ~18 fold enrichment for the ERE alone suggesting a strong evolutionary selection for 




Figure 63. The presence of ERα, FOXA1 and GATA3 recognition motifs. The position 
weight matrix from de novo motif finding by the Pomoda (Peak Oriented Motif 
Discovery Algorithm) was used to screen for the co-existing of the TF’s motif in the 
human genome as compared to the random sequences of 200Mb with the cutoff of 1E-4. 
There is a 64-fold enrichment for the co-localization of ERα+FOXA1+GATA3 motif in 






An enhanceosome has been defined as protein complex composed of a repertoire of TFs 
that binds to the "enhancer" region of a gene and sequentially recruits components of the 
transcriptional machinery such as RNA polymerase to initiate the gene's transcription. 
Synergistic interplay among the members within the enhanceosome complex result in 
providing some functional specificity,  and a multiple gene "fail-safe" mechanism for 
controlling gene expression (Robert and Tom, 1994). It is suggested that an 
enhanceosome may provide functional redundancy that minimizes the chances that a 
gene may be switched off due to mutation, or permit activation of a gene by orchestrating 
multiple different signaling cascades (Farnham, 2009). The importance of enhanceosome 
formation is evidenced by the virus-inducible transcriptional activation of the human 
interferon-β (IFN-β) gene by the assembly of transcriptional activator (p50/ p65), IRF-1, 
ATF-2, c-Jun and high mobility group protein HMG I to the basal transcription complex 
(Maniatis, 1995). Chen X et al. (Chen et al, 2008) showed that TFs coordinately 
expressed in embryonic stem cell differentiation form specific enhanceosomes adjacent to 
cassettes of genes that demarcate different developmental functions. The present study 
provides evidence of how the ERα, FOXA1 and GATA3 enhanceosome regulate this 
multifaceted transcriptional network operative in reproduction and cancer. Furthermore, 
we show that this ERα+FOXA1+GATA3 enhanceosome recruits distinct components of 
active transcription regulatory machinery, namely RNA Pol II and p300, an 
acetyltransferase associated with enhancer activity as well as chromatin opening. 
Interestingly, the ERα, FOXA1 and GATA3 binding were also coincided with retinoic 
acid receptor binding (RAR) though the overlap is less frequent, suggesting that FOXA1 
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and GATA3 could have a broader “universal” co-regulator function  for nuclear hormone 
binding (Hua S. et al, 2009).  
It is known that FOXA1 and GATA3 are important regulatory proteins in their own right. 
FOXA1 has winged helix domains that can structurally mimic histone H1 and H5, and 
thus permits its interaction with histone H3 and H4. This unique feature of FOXA1 
allows it to bind to the specific DNA sequences on the nucleosome core and displace the 
linker histones, leading to de-compaction of chromatin and to facilitate the binding of 
other TFs (Cirillo et al, 1998; Clark et al, 1993; Kaestner, 2000). It is suggested that 
ERα+FOXA1 regulated network establishes  a ‘one-step forward’ (through cyclin D1 
induction) and ‘one-step backward’ (through p27KIP1 induction) manner to control cell 
cycle progression in breast cancer cells (Nakshatri and Badve, 2009). Recent work by 
Lupien et al. (Lupien et al, 2008) revealed that there was significant overlap of FOXA1 
occupied sites on ERα cistrome, hence suggesting that FOXA1 contributed in the control 
of E2 signaling in breast cancer cells.  
GATA3 plays essential roles in the mammary gland morphogenesis and lactogenesis. 
Inactivation of GATA3 resulted in diminished mammary epithelial structure, severely 
impaired lactogenesis and disrupted differentiation of luminal progenitor cells into ductal 
and alveolar cells (Asselin-Labat et al, 2007). Moreover, GATA3 is also involved in the 
positive cross-regulatory loop with ERα in breast cancer cells in mediating the E2 
signaling (Eeckhoute et al, 2007) . Clinically, both FOXA1 and GATA3 are known to be 
co-expressed in ER positive breast cancers. In addition, Mehra et al. (Mehra et al, 2005) 
reported that low levels of GATA3 was strongly associated with larger tumor size, 
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positive lymph node status, higher histology grade, ERα-negative status, Her2-neu 
overexpression as well as increased risk for recurrence and metastasis. Taken together, 
we posit that such a complex regulatory and functional interaction of three TFs each 
subserving important functions is another evolutionary strategy to ensure the balanced 
co-regulation of gene networks important in mammalian reproduction.    
Here, we have shown that the effects of the ERα+FOXA1+GATA3 enhanceosome 
expression is the regulation of the major important E2-responsive genes associated with 
various signaling pathways, biology processes and molecular functions previously 
ascribed to ER alone.   
Though the presence of an ERα is necessary for E2 induced growth in responsive cells, its 
presence is not sufficient for cellular proliferation, and in fact, the introduction of ERα or 
FOXA1 into ERα negative cell lines such as MDA-MB-231 and BT-549 leads to cell 
cycle arrest.  Importantly, we show that transfection of the three TFs into the ERα 
negative cell lines, MDA-MB-231 and BT-549, could reprogram the cell to be estrogen 
responsive for cell proliferation, counteracting the growth inhibitory action of unaided 
FOXA1 or ER. A possible explanation for this phenomenon is that the high levels of 
exogenous TFs simply saturate the transcriptional and translational machinery of the cell 
and thus actively outcompete the original transcriptional program. This cellular 
reprogramming is correlated with reconstruction of the approximate transcriptional 
cassette of the modified MDA-MB-231 and BT-549 to partially resemble that of E2 
stimulated MCF-7 cells.  Thus, it appears that the primary role of FOXA1 and ER alone 
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in breast cancer cells is as a growth or tumor inhibitor, but that the conditional expression 
of ERα, FOXA1, and GATA3 reverses this state to that of growth induction.  We have 
revealed that FOXA1 and GATA3 are essential components in maintaining the 
dependence of ERα-positive breast cancer cells to estrogen for proliferation. Hence, the 
presence of FOXA1 and GATA3 may help to prevent the breast cancer cells from 
progressing from a good prognosis group that responds to endocrine treatment to a bad 
prognosis group that gained anti-estrogen resistance or estrogen independent growth. 
Intriguingly, enforced expression of the triple factors, ER, FOXA1, and GATA3, also 
induced a modest basal to luminal expression cassette change by reducing the basal 
signature and increasing the luminal signature in MDA-MB-231 and BT-549 cells not 
seen in the ER-alone transfected clone.  Our results suggest that the conjoint effects by 
the three TFs could formulate a luminal cassette and then manifest the proliferative 
phenotype in response to estrogen stimulation.  
Our work also sheds some light on the functional role of FOXA1, which is thought to be 
a pioneering factor for nuclear hormone receptors such as the estrogen receptor and 
androgen receptor (Carroll et al, 2005). As a pioneering factor, FOXA1 may function to 
open chromatin structures so as to facilitate ERα binding to its cognate response elements. 
Indeed, our chromatin model predictive of ERα binding includes FOXA1 occupancy in 
the preligand (before E2 exposure) state (Joseph et al, 2010). However, these studies did 
not examine the dynamic relationship of ERα and FOXA1 occupancy before and after 
ligand exposure. Our results suggest that ERα is as likely to be a pioneering factor to 
recruit FOXA1 as the converse.  
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Recently, Eeckhoute et al. (Eeckhoute et al, 2009) reported that a significant fraction of 
FOXA1-bound sites have a relatively closed chromatin conformation that is unrelated to 
gene expression suggesting that FOXA1 may require a repertoire of collaborating TFs to 
promote chromatin opening. Our findings suggest that ERα is one such collaborating 
transcription factor with GATA3 playing a more minor role. 
Each transcriptional activation comprises a series of events, such as DNA methylation, 
histone modification, cofactor modulation, each of which alone might not be sufficient 
for full activation, but together converge to define a specific ‘combinatorial code’. Our 
work has provided strong evidence to illustrate this combinatorial code orchestrated by 
ERα, FOXA1 and GATA3 enhanceosome that exerts great impact on the transcriptome 
and cellular growth of breast cancer cells. In contrast, in the collaborative work with 
Pervaiz and co-workers (Zhou et al, in preparation), we revealed that there was 
competition between activated ERα and Peroxisome-Proliferator-Activated Receptor-γ 
(PPAR-γ), leading to suppressed recruitment of these TFs to the cis-regulatory regions 
and consequently down-regulate the targeted genes. Interestingly, the work by 
Katzenellenbogen and co-workers has uncovered the mutual restriction and competitive 
selection models whereby the dominant ERα is capable of displacing ERβ binding events 
when both ERα and ERβ were co-expressed and activated (Charn et al, 2010).  
Cumulatively, these findings have further elaborated the various transcriptional models 
involving different TF players that synergistically orchestrate the transcription networks 





Figure 64. The various transcription activation models involving different players to 
orchestrate the transcription machinery of breast cancer cells. (A) The mutual restriction 
and competitive selection models reveal that the dominant ERα is capable in displacing 
ERβ binding events when both ERα and ERβ were co-expressed and activated. (B) The 
competitive model between two transcription factors that prevents their recruitment to 
cis-regulatory region, leading to inhibited transcription. (C) The conjoint action by the 








CHAPTER 7: CONCLUSION 
Though numerous expression profiling studies on breast tumors have implicated the co-
expression of ERα, FOXA1 and GATA3 in the luminal subtype patient, the nature of 
their coordinated interaction at the genome level and their biological consequences 
remain poorly understood. 
My work provided evidence on how the ERα, FOXA1 and GATA3 converge to form the 
enhanceosome that exerts a specific combinatorial code to regulate the multifaceted 
transcriptional network operative in reproduction and cancer. Furthermore, we show that 
this ERα+FOXA1+GATA3 enhanceosome recruits distinct components of active 
transcription regulatory machinery, namely RNA Pol II and p300, an acetyltransferase 
associated with enhancer activity as well as chromatin opening. The enhanceosome also 
exerts the greatest impacts in regulating the estrogen-responsive genes and activate the 
various signaling pathways, biological processes and molecular functions previously 
ascribed to ER alone.   
The chromatin landscape is organized into higher-order folding and three-dimensional 
structures that influence the transcriptional circulatory. In our work, we revealed that the 
ERα+FOXA1+GATA3 enhanceosome is associated with vast majority of the complex 
ERα long-range interactome, suggesting that the enhanceosome components are essential 




Despite the role of the ERα pathway as a key growth driver for breast cells, the 
phenotypic consequence of exogenous introduction of ERα into ERα-negative cells 
paradoxically has been growth inhibition. Importantly, our study has resolved this 
physiologic and cellular contradiction by demonstrating the competence of these three 
TFs to reprogramme the ERα-negative breast cancer cells to acquire the appropriate 
transcriptome profile and cellular growth resemble to an ERα-positive breast cancer line. 
The present study also uncovered potential mechanistic insights on how the 
ERα+FOXA1+GATA3-expressing cells can positively regulate the growth genes as 
opposed to the ERα-only cells.  
This study contributes to the accumulating body of data which will ultimately provide a 
systems perspective of the gene regulatory networks in hormonal carcinogenesis and 
should be of interest to basic and clinical researchers involved in studies of 
transcriptional regulatory mechanisms and their roles in cancer cell proliferation. 
Taken together, we have uncovered the functional importance of an enhanceosome 
comprising ERα, FOXA1 and GATA3 in the estrogen responsiveness of ERα positive 
breast cancer cells. The findings described herein have further refined our understanding 
on the combinatorial control of the enhanceosome-driven transcriptional activation and 
illuminate a novel role of this enhanceosome component in regulating the growth and 
proliferation of ERα positive breast cancer cells. 
In our future study, we are expanding the work to uncover the core cassette of genes that 
drive the proliferation of breast cancer cells with the ultimate aim to identify new 





Figure 65. The model of enhanceosome-mediated transcriptional activation in breast 
cancer cells. Upon estrogen stimulation, the ERα will bind to the cis-regulatory regions 
individually or in co-operation with FOXA1 or GATA3. Importantly, we revealed that in 
the ligand-stimulated condition, ERα, FOXA1 and GATA3 will converge to form the 
enhanceosome that exerts greatest transcriptional and physiological impacts in breast 
cancer cells. This enhanceosome is essential in regulating the estrogen-responsive genes, 
activating the various signaling pathways and possibly mediating the ERα long-range 
interactome. Importantly, we demonstrated that the enhanceosome is competent to 
reprogramme the ERα-negative cells to acquire the appropriate transcription profile and 
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